Sulfoalkyl ether cyclodextrin compositions

ABSTRACT

SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.16/181,233, filed Nov. 5, 2018, which is a continuation of U.S.application Ser. No. 14/954,772, filed Nov. 30, 2015, which is acontinuation of U.S. application Ser. No. 13/789,598, filed Mar. 7,2013, which is a continuation of U.S. application Ser. No. 12/613,103,filed Nov. 5, 2009, which is a continuation of U.S. application Ser. No.12/404,174, filed Mar. 13, 2009, which claims the benefit of U.S.Provisional Application No. 61/048,518, filed Apr. 28, 2008, all ofwhich are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION Field of the Invention

The present invention relates to compositions comprising sulfoalkylether cyclodextrin (“SAE-CD”) compositions, and methods for preparingand using the same.

Background of the Invention

Sulfoalkyl ether cyclodextrin (“SAE-CD”) derivatives are polyanionic,hydrophilic, water-soluble cyclodextrins derivatized with sulfoalkylether functional groups. An anionic sulfoalkyl ether substituentdramatically improves the aqueous solubility and safety compared to anunderivatized cyclodextrin. Reversible, non-covalent, complexation ofdrugs with sulfoalkyl ether-substitutes cyclodextrins generally allowsfor increased solubility of an active pharmaceutical ingredient and, insonic cases, increased stability of drugs in aqueous solutions.

A sulfobutyl ether-β-cyclodextrin having an average degree ofsubstitution of about seven (7) is currently marketed as CAPTISOL®(CyDex Pharmaceuticals, Inc., Lenexa, Kans.). CAPTISOL has the followingchemical structure:

wherein R is (—H)_(21-n) or (—CH₂CH₂CH₂CH₂SO₃ ⁻Na⁺)_(n), and n is 6-7.1.

Sulfoalkyl ether-substituted cyclodextrins can be manufactured accordingto the processes disclosed in, e.g., U.S. Pat. Nos. 5,134,127, 5,376,645and 6,153,746, which are herein incorporated by reference in theirentirety. The SAE-CD derivatives or cyclodextrin derivatives containinga sulfonate functional group can also be made according to Parmerter etal. (U.S. Pat. No. 3,426,011); Gadelle et al. (U.S. Pat. No. 5,578,719);Joullie et al. (U.S. Pat. Nos. 5,760,015 and 5,846,954); Buchanan et al.(U.S. Pat. Nos. 6,610,671 and 6,479,467); Perrier et al. (U.S. Pat. No.6,524,595); Uchiyama et al. (U.S. Pat. No. 5,512,665); Lammers et al.,Recl. Trav. China. Pays-Bas 91:733 (1972); Staerke 23:167 (1971); Qu etal., J. Inclusion Phenom. Macro. Chem. 43:213 (2002); Yoshinaga,Japanese Patent No. JP 05001102; U.S. Pat. No. 5,241,059; PCTInternational Publication No. WO 01/40316, Adam et al., J. Med. Chem.45:1806 (2002); and Tarver et al., Bioorg. Med. Chem. 10:1819 (2002).

Impurities present in a SAE-CD composition can thus reduce theshell-life and potency of an active agent composition. Impurities can beremoved from a cyclodextrin or SAE-CD composition by exposure to (e.g.,mixing with) activated carbon. The treatment of cyclodextrin-containingaqueous solutions and suspensions with activated carbon is known. See,e.g., U.S. Pat. Nos. 4,738,923, 5,393,880 and 5,569,756. However, thereis a continued need for SAE-CD compositions with higher purity.

BRIEF SUMMARY OF THE INVENTION

The present invention demonstrates that substantial removal of both aphosphate and a drug-degrading impurity from a SAE-CD compositionprovides a composition that can be readily mixed with an active agent toprovide a high-stability formulation.

The present invention is directed to a SAE-CD composition comprising asulfoalkyl ether cyclodextrin and less than 100 ppm of a phosphate,wherein the SAE-CD composition has an absorption of less than 0.5 A.U.due to a drug-degrading agent, as determined by UV/vis spectrophotometryat a wavelength of 245 nm to 270 nm for an aqueous solution containing300 mg of the SAE-CD composition per mL of solution in a cell having a 1cm path length.

The present invention is directed to a composition comprising anexcipient and a SAE-CD composition, wherein the SAE-CD compositioncomprises a sulfoalkyl ether cyclodextrin and less than 100 ppm of aphosphate, wherein the SAE-CD composition has an absorption of less than0.5 A.U. due to a drug-degrading agent, as determined by UV/visspectrophotometry at a wavelength of 245 nm to 270 nm for an aqueoussolution containing 300 mg of the SAE-CD composition per mL of solutionin a cell having a 1 cm path length.

The present invention is directed to a composition comprising one ormore active agents and a SAE-CD composition, wherein the SAE-CDcomposition comprises a sulfoalkyl ether cyclodextrin and less than 100ppm of a phosphate, wherein the SAE-CD composition has an absorption ofless than 0.5 A.U. due to a drug-degrading agent, as determined byUV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for anaqueous solution containing 300 mg of the SAE-CD composition per mL ofsolution in a cell having a 1 cm path length.

In some embodiments, the SAE-CD composition has an absorption of lessthan 0.2 A.U. due to a color-forming agent, as determined by UV/visspectrophotometry at a wavelength of 320 nm to 350 nm for an aqueoussolution containing 500 mg of the SAE-CD composition per mL of solutionin a cell having a 1 cm path length.

In some embodiments, the SAE-CD composition further comprises:

-   less than 20 ppm of a sulfoalkylating agent;-   less than 0.5% wt. of an underivatized cyclodextrin;-   less than 1% wt. of an alkali metal halide salt; and-   less than 0.25% wt. of a hydrolyzed sulfoalkylating agent.

In sonic embodiments, the SAE-CD composition has an absorption of lessthan 0.5 A.U. due to a drug-degrading agent, as determined by UV/visspectrophotometry at a wavelength of 245 nm to 270 nm for an aqueoussolution containing 500 mg of the SAE-CD composition per tuL of solutionin a cell having a 1 cm path length.

In some embodiments, the sulfoalkyl ether cyclodextrin is a compound ofFormula (1):

wherein p is 4, 5 or 6, and R₁ is independently selected at eachoccurrence from —OH or -SAE-T; and wherein -SAE- is independentlyselected at each occurrence from a —O—(C₇-C₆ alkylene)-SO₃ ⁻ group, and-T is independently selected at each occurrence from pharmaceuticallyacceptable cations, provided that at least one R₁ is —OH and at leastone R₁ is -SAE-T.

In some embodiments, -SAE- is a —O—(C₄ alkylene)-SO₃ ⁻ group at eachoccurrence, and -T is Na⁺ at each occurrence.

In some embodiments, the SAE-CD composition comprises:

-   less than 50 ppm of a phosphate;-   less than 10 ppm of a sulfoalkylating agent;-   less than 0.2% wt. of an underivatized cyclodextrin;-   less than 0.5% wt. of an alkali metal halide salt; and-   less than 0.1% wt. of a hydrolyzed sulfoalkylating agent;-   wherein the SAE-CD composition has an absorption of less than 0.5    A.U. due to the drug-degrading agent, as determined by UV/vis    spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous    solution containing 500 mg of the SAE-CD composition per mL of    solution in a cell having a 1 cm path length; and-   wherein the SAE-CD composition has an absorption of less than 0.2    A.U. due to the color-forming agent, as determined by LTV/vis    spectrophotometry at a wavelength of 320 nm to 350 nm for an aqueous    solution containing 500 mg of the SAE-CD composition per mL of    solution in a cell having a 1 cm path length.

In some embodiments, the SAE-CD composition comprises:

-   less than 10 ppm of a phosphate;-   less than 2 ppm of a sulfoalkylating agent;-   less than 0.1% wt. of an underivatized cyclodextrin;-   less than 0.2% wt. of an alkali metal halide salt; and-   less than 0.08% wt. of a hydrolyzed sulfoalkylating agent;-   wherein the SAE-CD composition has an absorption of less than 0.25    A.U. due to the drug-degrading agent, as determined by UV/vis    spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous    solution containing 500 mg of the SAE-CD composition per mL of    solution in a cell having a 1 cm path length; and wherein the SAE-CD    composition has an absorption of less than 0.1 A.U. due to the    color-forming agent, as determined by UV/vis spectrophotometry at a    wavelength of 320 nm to 350 nm for an aqueous solution containing    500 mg of the SAE-CD composition per mL, of solution in a cell    having a 1 cm path length.

In some embodiments, the SAE-CD composition comprises:

-   less than 5 ppm of a phosphate;-   less than 2 ppm of a sulfoalkylating agent;-   less than 0.1% wt. of an alkali metal halide salt; and-   less than 0.05% wt. of a hydrolyzed sulfoalkylating agent.

The present invention is also directed to a composition comprising anexcipient and a SAE-CD composition, wherein the SAE-CD compositioncomprises a sulfobutyl ether cyclodextrin having an average degree ofsubstitution of 7 and less than 100 ppm of a phosphate, wherein theSAE-CD composition has an absorption of less than 0.5 A.U. due to adrug-degrading agent, as determined by UV/vis spectrophotometry at awavelength of 245 nm to 270 nm for an aqueous solution containing 500 mgof the SAE-CD composition per mL of solution in a cell having a 1 cmpath length.

The present invention is also directed to a composition comprising oneor more active agents and a SAE-CD composition, wherein the SAE-CDcomposition comprises a sulfobutyl ether cyclodextrin having an averagedegree of substitution of 7 and less than 100 ppm of a phosphate,wherein the SAE-CD composition has an absorption of less than 0.5 A.U.due to a drug-degrading agent, as determined, by UV/visspectrophotometry at a wavelength of 245 nm to 270 nm for an aqueoussolution containing 500 mg of the SAE-CD composition per mL of solutionin a cell having a 1 cm path length.

In some embodiments, a SAE-CD composition can comprise:

-   less than about 250 ppb of sulfoalkylating agent;-   less than about 0.1% wt., less than 0.08% wt., or less than 0.5% wt.    of underivatized. cyclodextrin;-   less than 200 ppm, less than 150 ppm, less than 100 ppm, less than    50 ppm, 20 ppm, less than 10 ppm, less than 5 ppm, or less than 2    ppm of phosphate;-   less than 1% wt., less than 0.5% wt., less than 0.2% wt., less than,    0.1% wt., less than, 0.08% wt., or less than, 0.05% wt. of alkali    metal halide salt;-   less than 1% wt., less than 0.5% wt, less than 0.25% wt., less than    0.1% wt., less than 0.08% wt., or less than 0.05% wt. of hydrolyzed    sulfoalkylating agent;-   less than about 0.5, less than about 0.25, less than 0.2, less than    about 0.15, less than about 0.1, and less than 0.05 Absorbance Units    (“A.U.”) of drug-degrading agent, as determined using a U.V.    spectrophotometer and as measured at 245 nm to 270 nm by U.V.    spectrophotometry fir an aqueous solution containing about 500 mg    SAE-CD per mL;-   less than about 0.2, less than about 0.1, less than 0.05, less than    about 0.01 A.U. of drug-degrading agent, as determined by a    UV/visible spectrophotometer and as measured between 320 nm to 350    nm for an aqueous solution containing about 500 mg SAE-CD per mL.

The SAE-CD composition can be prepared by direct derivatization of anunderivatized α-, β-, or γ-cyclodextrin or by further derivatization ofa previously prepared cyclodextrin derivative. Such methods ofderivatization include alterations in the known sequence of chemicalsynthetic steps for the preparation of water-soluble cyclodextrinderivatives. Suitable methods are described herein.

In some embodiments, the SAE-CD composition has an absorption of lessthan 0.2 A.U. due to a color-forming agent, as determined by UV/visspectrophotometry at a wavelength of 320 nm to 350 nm for an aqueoussolution containing 500 mg of the SAE-CD composition per mL of solutionin a cell having a 1 cm path length.

In some embodiments, the SAE-CD composition further comprises one ormore excipients.

The present invention is also directed to a process for preparing aSAE-CD composition comprising a sulfoalkyl ether cyclodextrin, theprocess comprising:

-   (a) mixing in an aqueous medium a cyclodextrin with a    sulfoalkylating agent in the presence of an alkalizing agent to form    an aqueous reaction milieu comprising a sulfoalkyl ether    cyclodextrin, one or more unwanted components, and one or more    drug-degrading impurities;-   (b) conducting one or more separations to remove the one or more    unwanted components from the aqueous milieu to form a partially    purified aqueous solution comprising the sulfoalkyl ether    cyclodextrin and the one or more drug-degrading impurities, wherein    the one or more separations include a process selected from:    ultrafiltration, diafiltration, centrifugation, extraction, solvent    precipitation, and dialysis; and-   (c) treating the partially purified aqueous solution with a    phosphate-free activated carbon to provide the SAE-CD composition    comprising the sulfoalkyl ether cyclodextrin and less than 100 ppm    of a phosphate, wherein the SAE-CD composition has an absorption of    less than 0.5 A.U. due to a drug-degrading agent, as determined by    UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an    aqueous solution containing 300 mg of the SAE-CD composition per mL    of solution in a cell having a 1 cm path length.

The present invention is also directed to a process for preparing acomposition. comprising an excipient and a SAE-CD composition, whereinthe SAE-CD composition comprises a sulfoalkyl ether cyclodextrin, theprocess comprising:

-   (a) mixing in an aqueous medium a cyclodextrin with a    sulfoalkylating agent in the presence of an alkalizing agent to form    an aqueous reaction milieu comprising a sulfoalkyl ether    cyclodextrin, one or more unwanted components, and one or more    drug-degrading impurities;-   (b) conducting one or more separations to remove the one or more    unwanted components from the aqueous milieu to form a partially    purified aqueous solution comprising the sulfoalkyl ether    cyclodextrin and the one or more drug-degrading impurities, wherein    the one or more separations include a process selected from:    ultrafiltration, diafiltration, centrifugation, extraction, solvent    precipitation, and dialysis;-   (c) treating the partially purified aqueous solution with a    phosphate-free activated carbon to provide the SAE-CD composition    comprising the sulfoalkyl ether cyclodextrin and less than 100 ppm    of a phosphate, wherein the SAE-CD composition has an absorption of    less than 0.5 A.U. due to a drug-degrading agent, as determined by    UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an    aqueous solution containing 300 mg of the SAE-CD composition per ml,    of solution in a cell having a 1 cm path length; and-   (d) combining the SAE-CD composition with an excipient.

The present invention is also directed to a process for preparing acomposition comprising one or more active agents and a SAE-CDcomposition, wherein the SAE-CD composition comprises a sulfoalkyl ethercyclodextrin, the process comprising:

-   (a) mixing in an aqueous medium a cyclodextrin with a    sulfoalkylating agent in the presence of an alkalizing agent to form    an aqueous reaction milieu comprising a sultbalkyl ether    cyclodextrin, one or more unwanted components, and one or more    drug-degrading impurities;-   (b) conducting one or more separations to remove the one or more    unwanted components from the aqueous milieu to form a partially    purified aqueous solution comprising the sulfoalkyl ether    cyclodextrin and the one or more drug-degrading impurities, wherein    the one or more separations include a process selected from:    ultrafiltration, diafiltration, centrifugation, extraction, solvent    precipitation, and dialysis;-   (c) treating the partially purified aqueous solution with a    phosphate-free activated carbon to provide the SAE-CD composition    comprising the sulfoalkyl. ether cyclodextrin and less than 100 ppm    of a phosphate, wherein the SAE-CD composition has an absorption of    less than 0.5 A.U. due to a drug-degrading agent, as determined by    UV vis spectrophotometry at a wavelength of 245 nm to 270 nm for an    aqueous solution containing 300 mg of the SAE-CD composition per mL    of solution in a cell having a 1 cm path length; and-   (d) combining the SAE-CD composition with one or more active agents.

The present invention is also directed to a process comprising: mixingin an aqueous medium a cyclodextrin with sulfoalkylating agent in thepresence of an alkalizing agent, thereby forming an aqueous reactionmilieu comprising SAE-CD, one or more unwanted components, and one ormore drug-degrading impurities; conducting one or more separationsand/or purifications to remove the one or more unwanted components fromthe aqueous milieu thereby forming a partially purified aqueous solutioncomprising SAE-CD and one or more drug-degrading impurities; andrepeatedly treating the partially purified aqueous solution withactivated carbon, thereby eliminating or substantially reducing theamount of the one or more drug-degrading impurities therein and forminga aqueous composition comprising SAE-CD. The process can furthercomprise optionally degrading or removing excess sulfoalkylating agent,if any, present in the aqueous reaction milieu after formation of SAE-CDor after completion of the mixing. The process can further compriseoptionally quenching the reaction.

The present invention is also directed to a product prepared by theabove processes.

In some embodiments, the sulfoalkyl ether cyclodextrin in the processesof the present invention is a compound of Formula (1):

wherein p is 4, 5 or 6, and R₁ is independently selected at eachoccurrence from —OH or -SAE-T; and wherein -SAE- is independentlyselected at each occurrence from a —O—(C₂-C₆ alkylene)-SO₃ ⁻ group, and-T is independently selected at each occurrence from pharmaceuticallyacceptable cations, provided that at least one R₁ is —OH and at leastone R₁ is -SAE-T.

In some embodiments, -SAE- is a —O—(C₄ alkylene)-SO₃ ⁻ group at eachoccurrence, and -T is Na⁺ at each occurrence.

In some embodiments, the treating comprises:

adding a phosphate-free particulate or powdered activated carbon to thepartially purified aqueous solution while mixing, separating theactivated carbon from the solution, and repeating the adding and theseparating at least once until the amount of drug-degrading agent in.the solution is reduced to a target level; or

passing and recycling the partially purified aqueous solution through amass of phosphate-free activated carbon in a flow-through apparatusuntil the amount of drug-degrading agent in the solution is reduced to atarget level.

In some embodiments, the conducting comprises passing and recycling twoor more times, wherein each passing is with a different mass ofactivated carbon.

In some embodiments, the activated carbon present during the conductingis about 12% by weight of the sulfoalkyl ether cyclodextrin, and theconducting is performed for at least about 2 hours.

In some embodiments, the mixing comprises: providing an aqueous alkalinecomposition comprising a cyclodextrin and adding to the composition asulfoalkylating agent. In some embodiments, the mixing comprisesproviding a sulfoalkylating agent composition and adding to thecomposition an aqueous alkaline composition comprising a cyclodextrin.

The mixing can comprise: combining in an aqueous reaction medium anunsubstituted cyclodextrin starting material, and an alkyl sultone in anamount sufficient to effect a pre-determined degree of substitution, inthe presence of a base to effect sulfoalkylation of the cyclodextrin;maintaining the pH of the reaction medium basic but at a level betweenabout 9 and about 11 during the sulfoalkylation for a time sufficient toconsume the cyclodextrin such that residual unreacted cyclodextrinreaches a level of less than 0.5% by weight based on the original weightof unsubstituted cyclodextrin starting material; adding base in anamount sufficient to effect completion of the sulfoalkylation; andadding, additional base following the completion, the base being addedin an amount and under conditions sufficient to effect destruction ofresidual alkylsultone to a level less than 20 ppm or less than 2 ppmbased on the weight of the solution.

In some embodiments, the mixing can comprise: combining in an aqueousreaction medium an unsubstituted cyclodextrin starting material with analkyl sultone in an amount sufficient to effect a pre-determined degreeof substitution, in the presence of an alkali metal hydroxide;conducting sulfoalkylation of the cyclodextrin at a pH of about 8 toabout 11 until residual unreacted cyclodextrin is less than 0.5% byweight, or less than 0.1%; adding additional hydroxide in an amountsufficient to achieve the degree of substitution and allowing thesulfoalkylation to proceed to completion; and adding additionalhydroxide following the completion, the hydroxide being added in anamount and under conditions sufficient to effect destruction of residualalkyl sultone to a level less than 20 ppm or less than 2 ppm based onthe weight of the solution.

Degrading an excess sulfoalkylating agent can be required whereunacceptable amounts of sulfoalkylating agent are present in thereaction milieu following termination of the mixing. Degrading can beconducted by: exposing the reaction milieu to an elevated temperature ofat least 60° C., 60° C. to 85° C., or 60° C. to 80° C., for a period ofat least 6 hours, or 6 hours to 72 hours, thereby degrading thesulfoalkylating agent in situ and reducing the amount of, oreliminating, the sulfoalkylating agent in the aqueous liquid.

Quenching can be conducted after a degrading is performed, or after amixing but before a separating and/or one or more purifications.Quenching generally comprises: adding an acidifying agent to an alkalineSAE-CD containing solution to adjust the pH to about 5 to about 9, orabout 6 to about 8, or about 6.5 to about 7.5.

In some embodiments, the process comprises conducting one or moreseparations to remove the one or more unwanted components from theaqueous milieu to form a partially purified aqueous solution comprisingthe sulfoalkyl ether cyclodextrin and the one or more drug-degradingimpurities, wherein the one or more separations include a processselected from: ultrafiltration, diafiltration, centrifugation,extraction, solvent precipitation, and dialysis.

The separations can comprise: filtering the aqueous reaction milieuthrough a filtration medium to remove suspended solids and keep thefiltrate; or centrifuging the aqueous reaction milieu and separating andkeeping the supernatant; or extracting the suspended solids orimpurities.

The purifications can comprise: dialyzing the reaction milieu or aliquid obtained therefrom. Dialyzing can be conducted by diafiltration,ultrafiltration and/or nanofiltration.

In some embodiments, the process comprises repeating one or more of theseparations and/or purification. Repeatedly treating (i.e., treatingmore than once) can comprise: adding a granular or powdered activatedcarbon and/or other inert materials to the partially purified aqueoussolution while mixing, separating the activated carbon from thesolution, and. repeating each adding and separating at least once or twoor more times until the amount of drug-degrading agent(s) in thesolution is reduced to at or below a target level; or passing andrecycling the partially purified aqueous solution through a mass ofactivated carbon in a flow-through apparatus until the amount ofdrug-degrading agent(s) in the solution is reduced to at or below atarget level. Repeatedly treating can concomitantly remove one or moreother unwanted components, such as color-forming agent(s), protein,mineral, amino acid, metals, and carbon-adsorbable compound(s), in thepartially purified. solution.

The invention also provides a method of preparing a grade of SAE-CD byfollowing these and other known methods of preparing SAE-CD with theexception that activated carbon not activated with phosphoric acid isused and multiple treatments with activated carbon are employed in theprocess. The activated carbon has a high surface area, meaning smallparticle size, and the process can be conducted in a batchwise orcontinuous format. The activated carbon can be powdered, granular, orencased within a flow-through apparatus.

The invention also provides a thermal method for reducing the amount ofa sulfoalkylating agent in an aqueous liquid comprising a SAE-CD one ormore other components, the method comprising exposing the aqueous liquidto elevated temperatures of at least 25° C., or 25° C. to 75° C., for atleast 5 minutes, or 5 minutes to 200 minutes, thereby removin.g thesulfoalkylating agent in situ and reducing the amount of or eliminatingthe sulfoalkylating agent in the aqueous liquid.

In some embodiments, the invention provides a method of preparing aSAE-CD composition, the method comprising: exposing an initialcyclodextrin comprising at least one underivatized hydroxyl moiety, inaqueous alkaline media, to a substituent precursor for a period of timesufficient, at a temperature sufficient and at a solution pH sufficientto permit formation of a milieu comprising a cyclodextrin derivativecomposition having mon.ornodal, bimodal, trimodal or multi-modalsubstitution profile, and optionally processing the milieu to removeundesired components thereby forming the SAE-CD composition. Acyclodextrin starting material for use with the present invention caninclude an underivatized cyclodextrin, a previously derivatizedcyclodextrin, and combinations thereof.

In some embodiments, the invention provides a method of preparing aSAE-CD composition, the method comprising: providing a first liquidcomposition comprising substituent precursor; providing an alkalinesecond liquid composition comprising cyclodextrin (underivatized orderivatized); and adding the second liquid composition to the firstliquid composition for a period of time sufficient, at a temperaturesufficient and at a solution pH sufficient to permit formation of amilieu comprising a cyclodextrin derivative composition having amonomodal, bimodal, trimodal or multi-modal substitution profile, andoptionally processing the milieu to remove undesired components therebyforming the combination composition. In some embodiments, the secondliquid composition is added as a bolus, portionwise, dropwise,semi-continuously or continuously to the first liquid composition. Insome embodiments, both the first and second liquid compositions arealkaline.

In some embodiments, the invention provides a method of preparing aSAE-CD composition, the method comprising: exposing a cyclodextrinstarting material in neutral to alkaline aqueous media to substituentprecursor at a temperature and for a period of time sufficient toprovide an aqueous reaction milieu comprising SAE-CD, one or moreunwanted components, and one or more drug-degrading components;degrading any unreacted substituent precursor, if any, in the milieu;subjecting the milieu to one or more separations and/or purifications toform a partially purified aqueous liquid comprising SAE-CD and one ormore drug-degrading components; and treating the liquid with activatedcarbon at east two times to remove or reduce the amount ofdrug-degrading components present in the liquid, thereby forming anaqueous composition comprising SAE-CD.

The substituent precursor can be added incrementally or as a bolus, andthe substituent precursor can be added before, during or after exposureof the cyclodextrin starting material to the optionally alkaline aqueousmedia. Additional alkaline material or buffering material can be addedas needed to maintain the pH within a desired range. The derivatizationreaction can be conducted at ambient to elevated temperatures. Oncederivatization has proceeded to the desired extent, the reaction isoptionally quenched by addition of an acid. The reaction milieu isfurther processed (e.g., solvent precipitation, filtration,centrifugation, evaporation, concentration, drying, chromatography,dialysis, and/or ultra-filtration) to remove undesired materials andform the target composition. After final processing, the composition canbe in the form of a solid, liquid, semi-solid, gel, syrup, paste,powder, aggregate, granule, pellet, compressed material, reconstitutablesolid, suspension, glass, crystalline mass, amorphous mass, particulate,bead, emulsion, or wet mass.

In some embodiments, the SAE-CD composition comprises a plurality ofindividual SAE-CD derivatives that differ in individual degree ofsubstitution, such that the average degree of substitution for theSAE-CD composition is calculated, as described herein, from theindividual degrees of substitution of the species. The individualcyclodextrin derivative species can have the same substituent(s), butdiffer in the number of substituent(s) per cyclodextrin molecule, orcomprise different substituents that differ or are the same in numberper cyclodextrin molecule.

The cyclodextrin of the SAE-CD derivative can comprise an α-, β-, orγ-cyclodextrin, or a combination thereof.

The regioisomerism of derivatization by the sulfoalkyl ether (SAE)substituent can also be varied as desired such that a majority of thesubstituents present can be preferentially located at a primary hydroxylgroup or at one or both of the secondary hydroxyl groups of thecyclodextrin. In one embodiment, the primary distribution ofsubstituents is C-3>C-2>C-6, while in other embodiments the primarydistribution of substituents is C-2>C-3>C-6. The substitution pattern ofthe substituents can be determined by ¹H-NMR or ¹³C-NMR, as describedherein.

In some embodiments, a SAE-CD composition includes about 10% or less ofeach of an underivatized cyclodextrin. An underivatized cyclodextrin canbe added to a composition, can be in the composition due to incompleteremoval of a cyclodextrin starting material, and combinations thereof.

In some embodiments, a SAE-CD composition comprises a sulfoalkyl ethercyclodextrin comprising 50% or more, 50%, or less than 50% of thehydroxyl moieties being derivatized, in which all of the substituents ofthe sulfoalkyl ether cyclodextrin comprise similar alkylene (alkyl)radicals, or the substituents of the sulfoalkyl ether cyclodextrincomprise different alkylene (alkyl) radicals.

The SAE-CD composition of the invention can be used for substantiallyany known method or process wherein a cyclodextrin derivative providesutility. The composition can be used for the same process or method thatits starting cyclodextrin derivative compositions are used. Suitableuses for a combination composition of the invention include use inpharmaceutical or non-pharmaceutical formulation. The combinationcomposition of the invention can be used to solubilize, stabilize,taste-mask, suspend, immobilize, purify or extract one or more compoundsformulated therewith. An active combination composition comprising aSAE-CD composition and one or more therapeutically effective agents canbe used to treat (diagnose, prevent, cure, ameliorate, relieve, reducethe occurrence of, reduce the frequency of) a symptom, disease, ordisorder that is therapeutically responsive to the one or moretherapeutically effective agents.

In some embodiments, at least a portion of an active agent is complexedwith a sulfoalkyl ether cyclodextrin.

The composition of the invention can be employed in compositions,formulations, methods and systems as such those disclosed in U.S. Pat.Nos. 5,134,127, 5,376,645, 6,046,177, 5,914,122, 5,874,418, 7,034,013,6,869,939 and 6,133,248 U.S. Patent Pub. Nos. 2005/0164986,2005/0186267, 2007/0175472, 2005/0250738, 2007/0020299, 2007/0202054,2007/0020298, 2008/0194519, 2006/0258537, 2007/0020196; U.S. Appl. Nos.60/914,555 and 60/952,771; and International Appl. Nos. PCT/US05/38933,PCT/US06/62346, PCT/US07/7′1758, PCT/US07/71748, PCT/US07/72442,PCT/US07/72387 and PCT/US07/78465, the entire disclosures of which arehereby incorporated by reference. The SAE-CD of the invention can alsobe used as a suitable substitute for other known grades of SAE-CD,particularly those known grades having lower purity, thereby resultingin compositions and formulations have greater stability, e.g., greaterdrug stability.

The invention includes combinations and sub-combinations of the variousaspects and embodiments disclosed herein. These and other aspects ofthis invention will be apparent upon reference to the following detaileddescription, examples, claims, and attached drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated herein and form a partof the specification, illustrate one or more embodiments of the presentinvention and, together with the description, further serve to explainthe principles of the invention and to enable a person skilled in thepertinent art to make and use the invention. The following drawings aregiven by way of illustration only, and thus are not intended to limitthe scope of the present invention.

FIG. 1 provides a graphic representation of a UV/vis scan (190 nm to 400nm) of solutions containing a SAE-CD composition after a single carbontreatment, in which the sulfoalkyl ether cyclodextrin concentration isvaried from 1% to 60% by weight.

FIG. 2 provides a graphic representation of a UV/vis scan (190 nm to 400nm) of solutions containing a SAE-CD composition after a second carbontreatment, in which the sulfoalkyl ether cyclodextrin concentration isvaried from 1% to 60% by weight.

FIG. 3 provides a graphic representation of a UV/vis scan (190 urn to400 nm) of a SBE_(6.6)-β-CD solution after thermal and causticdegradation at a temperature of 60° C. for a period of 0, 24, 72, 96 and168 hours to demonstrate degradation of β-cyclodextrin and formation ofdrug-degrading impurities having an absorption at a wavelength of 245 nmto 270 nm and/or color-forming agents having an absorption at awavelength of 320 nm to 350 nm,

FIG. 4 provides a graphic representation of a UV scan (190 nm to 400 nm)of a solution containing a SAE-β-CD after exposure to a temperature of70° C. for a period of 48 hours, with subsequent treatment with varyingamounts of activated carbon.

FIG. 5 provides a graphic representation of the effect of initial UV/Visabsorption of a SBE_(6.6)-β-CD solution on API stability.

One or more embodiments of the present invention will now be describedwith reference to the accompanying drawings. In the drawings, likereference numbers can indicate identical or functionally similarelements. Additionally, the left-most digit(s) of a reference number canidentify the drawing in which the reference number first appears.

DETAILED DESCRIPTION OF THE INVENTION

This specification discloses one or more embodiments that incorporatethe features of this invention. The disclosed embodiment(s) merelyexemplify the invention. The scope of the invention is not limited tothe disclosed embodiment(s). The invention is defined by the claimsappended hereto.

References to spatial descriptions (e.g., “above,” “below,” “up,”“down,” “top,” “bottom,” etc.) made herein are for purposes ofdescription and illustration only, and should be interpreted asnon-limiting upon the processes, equipment, compositions and products ofany method of the present invention, which can be spatially arranged inany orientation or manner.

A SAE-CD composition of the invention provides unexpected advantagesover other compositions containing structurally related cyclodextrinderivative compositions. By “structurally related” is meant, forexample, that the substituent of the cyclodextrin derivative in thecomposition is essentially the same as the substituent of cyclodextrin.derivative to which it is being compared. Exemplary advantages caninclude an improved. ability of the combination composition to stabilizea neutral, cationic or anionic molecule, such as an active agent.

A “cyclodextrin derivative composition” is a composition having anaverage degree of substitution (“ADS”) for a specified substituent. Acyclodextrin derivative composition comprises a distribution ofcyclodextrin derivative species differing in the individual degree ofsubstitution specified substituent for each species, wherein thespecified substituent for each species is the same.

A composition of the invention can be a liquid, solid, suspension,colloid, pellet, bead, granule, film, powder, gel, cream, ointment,paste, stick, tablet, capsule, osmotic device, dispersion, emulsion,patch or any other type of formulation.

In some embodiments, a SAE-CD composition comprises a water-solublecyclodextrin derivative of Formula 1:

wherein: p is 4, 5 or 6;

R₁ is independently selected at each occurrence from —OH or -SAE-T;-SAE- is a —O—(C₂-C₆ alkylene)-SO₃ ⁻ group, wherein at least one SAE isindependently a —O—(C₂-C₆ alkylene)-SO₃ ⁻ group, a —O—(CH₂)₂SO₃ ⁻ group,wherein g is 2 to 6, or 2 to 4, (e.g. —OCH₂CH₂CH₂SO₃ ⁻ or—OCH₂CH₂CH₂CH₂SO₃ ⁻); and -T is independently selected at eachoccurrence from the group consisting of pharmaceutically acceptablecations, which group includes, for example, H⁺, alkali metals (e.g.,Li⁺, Na⁺, K⁺), alkaline earth metals (e.g., Ca⁺², Mg⁺²), ammonium ionsand amine cations such as the cations of (C₁-C₆)-alkylamines,piperidine, pyrazine, (C₁-C₆)-alkanolamine, ethylenediamine and(C₄-C₈)-cycloalkanolamine among others; provided that at least one R₁ isa hydroxyl moiety and at least one R₁ is -SAE-T.

When at least one R₁ of a derivatized cyclodextrin molecule is -SAE-T,the degree of substitution, in terms of the -SAE-T moiety, is understoodto be at least one (1). When the term -SAE- is used to denote asulfoalkyl-(alkylsulfonic acid)-ether moiety it being understood thatthe -SAE- moiety comprises a cation (-T) unless otherwise specified.Accordingly, the terms “SAE” and “-SAE-T” can, as appropriate, be usedinterchangeably herein.

Further exemplary SAE-CD derivatives include:

SAE_(x)-α-CD SAE_(x)-β-CD SAE_(x)-γ-CD SEE_(x)-α-CD SEE_(x)-β-CDSEE_(x)-γ-CD SPE_(x)-α-CD SPE_(x)-β-CD SPE_(x)-γ-CD SBE_(x)-α-CDSBE_(x)-β-CD SBE_(x)-γ-CD SPtE_(x)-α-CD SPtE_(x)-β-CD SPtE_(x)-γ-CDSHE_(x)-α-CD SHE_(x)-β-CD SHE_(x)-γ-CDwherein SEE denotes sulfoethyl ether, SPE denotes sulfopropyl ether, SBEdenotes sulfobutyl ether, SPtE denotes sulfopentyl ether, SHE denotessulfohexyl ether, and x denotes the average degree of substitution. Thesalts thereof (with “T” as cation) are understood to be present.

The SAE-CD compositions comprise a cyclodextrin derivatized with anionicsubstituents that can be present in different salt forms. Suitablecounterions include, but are not limited to, cationic organic atoms ormolecules and cationic inorganic atoms or molecules. The SAE-CDcompositions can include a single type of counterion or a mixture ofdifferent counterions, The properties of the SAE-CD compositions can bemodified by changing the identity of the counterion present. Forexample, a first salt form of a sulfoalkyl ether cyclodextrin canprovide a greater water activity reducing power than a different, secondsalt form of a sulfoalkyl ether cyclodextrin. Likewise, a sulfoalkylether cyclodextrin having a first degree of substitution can have agreater water activity reducing power than a second sulfoalkyl ethercyclodextrin having a different degree of substitution.

In some embodiments, a sulfoalkyl ether cyclodextrin possesses greaterwater solubility than a corresponding cyclodextrin from which a SAE-CDcomposition of the present invention is prepared. For example, in someembodiments, an underivatized cyclodextrin is utilized as a startingmaterial, e.g., α-, β- or γ-cyclodextrin, commercially available from,e.g., WACKER BIOCHEM CORP. (Adrian, Mich.), and other sources.Underivatized cyclodextrins have limited water solubility compared tothe SAE-CD compositions of the present invention. For example,underivatized α-CD, β-CD, γ-CD have a solubility in water solubility ofabout 145 g/L, 18.5 g/L, and 232 g/L, respectively, at saturation.

The water-soluble cyclodextrin derivative composition is optionallyprocessed to remove a major portion (e,g., >50%) of an underivatizedcyclodextrin, or other contaminants.

As used herein, a “substituent precursor” is used interchangeably withthe term “sulfoalkylating agent” and refers to an agent or combinationof agents and reaction conditions suitable for derivatizing a hydroxylgroup of a cyclodextrin with a sulfoalkyl ether substituent. Asubstituent precursor can react with an oxygen atom of a hydroxyl grouppresent on a cyclodextrin molecule to convert an —OH group to asulfoalkyl ether group. Exemplary sulfoalkylating agents suitable foruse with the present invention include, but are not limited to, an alkylsultone (e.g., 1,4-butane sultone, 1,5-pentane sultone, 1,3-propanesultone, and the like).

The terms “alkylene” and “alkyl,” as used herein (e.g., in the—O—(C₂-C₆-alkylene)SO₃ ⁻ group or in the alkylamine cations), includelinear, cyclic, and branched, saturated and unsaturated (i.e.,containing one or more double bonds), divalent alkylene groups andmonovalent alkyl groups, respectively. The term “alkanol” in this textlikewise includes both linear, cyclic and branched, saturated andunsaturated alkyl components of the alkanol groups, in which thehydroxyl groups can be situated at any position on the alkyl moiety. Theterm “cycloalkanol” includes unsubstituted or substituted (e.g., bymethyl or ethyl) cyclic alcohols.

The cyclodextrin derivatives of the present invention can differ intheir degree of substitution by functional groups, the number of carbonsin the functional groups, molecular weight, the number of glucopyranoseunits present in the base cyclodextrin, and/or substitution pattern. Inaddition, the derivatization of a cyclodextrin with functional groupsoccurs in a controlled, although not exact manner. For this reason, thedegree of substitution is actually a number representing the averagenumber of functional groups per cyclodextrin example, SBE₇-β-CD, has anaverage of 7 substitutions per cyclodextrin). Thus, it has an averagedegree of substitution (“ADS”) of about 7. In addition, theregiochemistry of substitution of the hydroxyl groups of thecyclodextrin is variable with regard to the substitution of specifichydroxyl groups of the hexose ring. For this reason, substitution of thedifferent hydroxyl groups is likely to occur during manufacture of thederivatized cyclodextrin, and a particular derivatized cyclodextrin willpossess a preferential, although not exclusive or specific, substitutionpattern. Given the above, the molecular weight of a particularderivatized cyclodextrin composition can vary from batch to batch.

Within a given cyclodextrin derivative composition, the substituents ofthe cyclodextrin derivative(s) thereof can be the same. For example, SAEmoieties can have the same type of alkylene (alkyl) radical upon eachoccurrence in a cyclodextrin derivative composition. In such anembodiment, the alkylene radical in the SAE moiety can be ethyl, propyl,butyl, pentyl or hexyl at each occurrence in a cyclodextrin derivativecomposition.

A cyclodextrin derivative composition comprises a distribution of aplurality of individual species, each species having an individualdegree of substitution (IDS). The content of each of the cyclodextrinspecies in a particular composition can be quantified using capillaryelectrophoresis. The method of analysis (capillary electrophoresis, forexample, for charged cyclodextrin derivatives) is sufficiently sensitiveto distinguish between compositions having only 5% or more of individualcyclodextrin derivative species.

A cyclodextrin molecule can comprise 3v+6 hydroxyl groups that areavailable for derivatization, where v is typically about 4 to about 10.For v=4 (α-CD), “y” (the degree of substitution) can be 1 to 17. For v=5(β-CD), “γ” (the degree of substitution) can be 1 to 20. For v=6 (γ-CD),“y” (the degree of substitution) can be 1 to 23. In general, “y” can bean integer of 1 to 3v+g, 1 to 2v+g, or 1 to 1v+g, where “g” is aninteger of 0 to 5.

The degree of substitution (“DS”) refers to the number of sulfoalkylether substituents attached to a cyclodextrin molecule, in other words,the moles of substituent groups per mole of cyclodextrin. Therefore,each substituent has its own DS for an individual cyclodextrinderivative species. The average degree of substitution (“ADS”) for asubstituent is a measure of the total number of substituents present percyclodextrin molecule for the distribution of cyclodextrin derivativeswithin a cyclodextrin derivative composition of the invention. Thus,SAE₄-CD has an ADS (per cyclodextrin molecule) of four (4).

A cyclodextrin derivative composition of the invention comprises adistribution of different individual cyclodextrin derivative species ormolecules. More specifically, a SAE-CD derivative composition comprisesplural SAE-CD species, each having a specific individual degree ofsubstitution with regard to the SAE substituent, As a consequence, theADS for SAE of a SAE-CD derivative composition represents an average ofthe individual DS (IDS) values of the population of individual moleculesin the composition. For example, a SAE_(5.2)-CD composition comprises adistribution of plural SAE_(x)-CD molecules, wherein x (the DS for SAEgroups) can vary from 1 to 10 or 1 to 11 for individual cyclodextrinmolecules. However, the population of SAE-CD molecules is such that theaverage value for x (the ADS for SAE groups) is 5.2.

The Average Degree of Substitution (“ADS”) for a cyclodextrin derivativecomposition can be calculated based upon the individual degree ofsubstitution according to Formula (I):

$\begin{matrix}{{ADS} = {\sum{\left( {\frac{({PAC})({MT})}{SCA} \times \; 100} \right)/100}}} & (I)\end{matrix}$

wherein “PAC” refers to the Peak Area Count; “MT” refers to theMigration Time; and “SCA” refers to the Summation of Corrected Area.These values can be obtained using, e.g., capillary electrophoresis. TheCorrected Area is the product of PAC×MT. The Individual Degree ofSubstitution (“IDS”) is the Corrected Area divided by the Summation ofCorrected Area [IDS=(PAC×MI)/SCA].

Variations among the individual cyclodextrin derivatives present in aSAE-CD composition can lead to changes in the complexation equilibriumconstant, K_(1:1), which in turn can affect the required molar ratioconcentration of a SAE-CD composition to form a complex with, e.g., anactive agent. The equilibrium constant can also be temperature-dependentand/or pH-dependent, and therefore allowances in the ratio of SAE-CDcomposition to active agent ratio are required such that an active agentremains solubilized during a temperature and/or pH fluctuation such ascan occur during manufacture, storage, transport, use, and the like. Theequilibrium constant can also vary due to the presence of otherexcipients (e.g., buffers, preservatives, antioxidants). Accordingly,the ratio of derivatized cyclodextrin to active agent can be varied fromthe ratios set forth herein in order to compensate for theabove-mentioned variables.

The SAE-CD compositions used to form the combination composition canindependently have a high to low ADS. The cyclodextrin derivativecompositions can also have a wide or narrow “span,” which refers to thenumber of individual species having a given degree of substitutionwithin a SAE-CD composition. For example, a cyclodextrin derivativecomposition comprising a single species of cyclodextrin derivativehaving a single specified individual degree of substitution has a spanof one, and in which case the individual degree of substitution of thecyclodextrin derivative equals the ADS of its cyclodextrin derivativecomposition. An electropherogram, for example, of a SAE-CD derivativewith a span of one should have only one SAE-CD species with respect todegree of substitution. A cyclodextrin derivative composition having aspan of two comprises two individual cyclodextrin derivative speciesdiffering in their individual degree of substitution, and itselectropherogram, for example, would indicate two different cyclodextrinderivative species differing in degree of substitution. Likewise, thespan of a cyclodextrin derivative composition having a span of threecomprises three individual cyclodextrin derivative species differing intheir individual degree of substitution. Since a combination compositionof the invention comprises two or more different cyclodextrin derivativecompositions, each having its own ADS, the span of the combinationcomposition will be at least 4, meaning that each starting cyclodextrinderivative composition has a span of at least two.

In some embodiments, a cyclodextrin starting material includes asecondary hydroxyl group on the C-2 and C-3 positions of theglucopyranose residues forming the cyclodextrin and a primary hydroxylon the C-6 position of the same. Each of these hydroxyl moieties isavailable for derivatization by substituent precursor. Depending uponthe synthetic methodology employed, the substituent moieties can bedistributed randomly or in a somewhat ordered manner among the availablehydroxyl positions. Some embodiments of the invention includes acyclodextrin derivative molecule wherein a minority of the substituentmoieties is located at the C-6 position, and a majority of thesubstituent moieties is located at the C-2 and/or C-3 position. Stillother embodiments of the invention includes a cyclodextrin derivativemolecule wherein the substituent moieties are substantially evenlydistributed among the C-2, C-3 and C-6 positions.

A combination composition of the invention can be prepared by: Method I,direct derivatization of an underivatized α-, β-, or γ-cyclodextrin); orMethod II, further derivatization of a previously prepared cyclodextrinderivative

The examples below detail several methods tier preparing a SAE-CDcomposition. In general, an underivatized cyclodextrin starting materialin neutral to alkaline aqueous media is exposed to substituentprecursor. The substituent precursor can be added incrementally or as abolus, and the substituent precursor can be added before, during orafter exposure of the cyclodextrin starting material to the optionallyalkaline aqueous media. Additional alkaline material or bufferingmaterial can be added as needed to maintain the pH within a desiredrange. The derivatization reaction can be conducted at ambient toelevated temperatures. Once derivatization has proceeded to the desiredextent, the reaction is optionally quenched by addition of an acid. Thereaction milieu is further processed (e.g., solvent precipitation,filtration, centrifugation, evaporation, concentration, drying,chromatography, dialysis, and/or ultrafiltration) to remove undesiredmaterials and form the target composition. After final processing, thecomposition can be in the form of a solid, liquid, semi-solid, gel,syrup, paste, powder, aggregate, granule, pellet, compressed material,reconstitutable solid, suspension, glass, crystalline mass, amorphousmass, particulate, bead, emulsion, or wet mass.

The invention provides a process of making a SAE-CD compositioncomprising a sulfoalkyl ether cyclodextrin, optionally having apre-determined degree of substitution, the process comprising: combiningan unsubstituted cyclodextrin starting material with an alkyl sultone inan amount sufficient to effect the pre-determined degree ofsubstitution, in the presence of an alkali metal hydroxide; conductingsulfoalkylation of the cyclodextrin within a pH of 9 to 11 untilresidual unreacted cyclodextrin is less than 0.5% by weight, or lessthan 0.1%; adding additional hydroxide in an amount sufficient toachieve the degree of substitution and allowing the sulfoalkylation toproceed to completion; and adding additional hydroxide to destroy anyresidual sultone.

Adding an additional hydroxide can be conducted using a quantity ofhydroxide, and under conditions (i.e., amount of additional hydroxideadded, temperature, length of time during which the sultone hydrolysisis conducted) such that the level of residual sultone in the aqueouscrude product is reduced to less than 20 ppm or less than 2 ppm.

It is possible that the reaction milieu or the partially purifiedaqueous solution will comprise unreacted sulfoalkylating agent. Thesulfoalkylating agent can be degraded in situ by adding additionalalkalizing agent or by heating a solution containing the agent.Degrading an excess sulfoalkylating agent will be required whereunacceptable amounts of sulfoalkylating agent are present in thereaction milieu following termination of the mixing. The sulfoalkylatingagent can be degraded in situ by adding additional alkalizing agent orby heating a solution containing the agent.

Degrading can be conducted by: exposing the reaction milieu to anelevated temperature of at least 60° C., at least 65° C., or 60° C. to85° C., 60° C. to 80° C. or 60° C. to 95° C. for a period of at least 6hours, at least 8 hours, 8 hours to 12 hours, 6 hours to 72 hours, or 48hours to 72 hours, thereby degrading the sulfoalkylating agent in situand reducing the amount of or eliminating the sulfoalkylating agent inthe aqueous liquid.

After the reaction has been conducted as described herein, the aqueousmedium containing the sulfoalkyl ether cyclodextrin can be neutralizedto a pH of about 7 in order to quench the reaction. The solution canthen be diluted with water in order to lower viscosity, particularly iffurther purification is to be conducted. Further purifications canemployed, including, but not limited to, diafiltration on anultrafiltration unit to purge the solution of reaction by-products suchas salts (e.g., NaCl if sodium hydroxide was employed as the base) andother low molecular weight by-products. The product can further beconcentrated by ultrafiltration. The product solution can then betreated with activated carbon in order to improve its color, reducebioburden, and substantially remove one or more drug degradingimpurities. The product can be isolated by a suitable drying techniquesuch as freeze drying, spray drying, or vacuum drum drying.

The reaction can be initially prepared by dissolving an unsubstrtutedα-, β-, or γ-cyclodextrin starting material in an aqueous solution ofbase, usually a hydroxide such as lithium, sodium, or potassiumhydroxide. The base is present in a catalytic amount (i.e., a molarratio of less than 1:1 relative to the cyclodextrin), to achieve apre-determined or desired degree of substitution. That is, the base ispresent in an amount less than one molar equivalent for each hydroxylsought to be derivatized in the cyclodextrin molecule. Becausecyclodextrins become increasingly soluble in aqueous solution as thetemperature is raised, the aqueous reaction mixture containing base andcyclodextrin should be raised to a temperature of about 50° C. to ensurecomplete dissolution. Agitation is generally employed throughout thecourse of the sulfoalkylation reaction.

After dissolution is complete, the alkyl sultone is added to start thesulfoalkylation reaction. The total amount of alkyl sultone addedthroughout the reaction will generally be in excess of thestoichiometric amount required to complete the reaction relative to theamount of cyclodextrin, since some of the alkylsultone is hydrolyzedand/or otherwise destroyed/degraded during the reaction such that it isnot available for use in the sulfoalkylation reaction. The exact amountof alkylsultone to use for a desired degree of substitution can bedetermined through the use of trial runs. The entire amount of alkylsultone needed to complete the reaction can be added prior to initiatingthe reaction. Because the system is aqueous, the reaction is generallyconducted at a temperature between 50° C. and 100° C. The reaction canbe conducted at a temperature less than 100° C., so that specializedpressure equipment is not required. In general, a temperature of 65° C.to 95° C. is suitable.

During the initial phase of the reaction (herein referred to as thepH-control phase), care should be taken to monitor the pH and maintainit at least basic, or in at a pH of about 8 to about 11. Monitoring ofpH can be effected conventionally as by using a standard pH meter.Adjustment of the pH can be effected by adding an aqueous solution ofhydroxide, e.g., a 10-15% solution. During the initial pH-control phase,unreacted cyclodextrin is reacted to the extent that less than 0.5% byweight, or less than 0.1% by weight, of unreacted cyclodextrin remainsin solution. Substantially the entire initial charge of cyclodextrin isthus reacted by being partially substituted, but to less than thedesired pre-determined degree of substitution. Residual cyclodextrin canbe monitored through out this initial phase, for example by HPLC asdescribed below, until a desired endpoint of less than 0.5%, or lessthan 0.1%, of residual cyclodextrin starting material, has beenachieved. The pH can be maintained and/or raised by adding concentratedhydroxide to the reaction medium continuously or in discrete amounts assmall increments. Addition in small increments is particularly suitable.

Once a sulfoalkylation procedure has been standardized or optimized sothat it is known that particular amounts of reactants can be combined ina procedure which produces the desired degree of substitution inconjunction with low residual cyclodextrin, then the procedure cansimply be checked at the end, as opposed to throughout or during theinitial pH-control, to ensure that a low level of residual (unreacted)cyclodextrin starting material has been achieved. The following tablesets forth a relationship between the amount of butane sultone chargedinto a reactor and the resulting average degree of substitution of theSAE-CD.

Butane Sultone Corresponding Charged Approximate (ApproximatePredetermined equivalents of ADS for BS per mole of SAE-CD cyclodextrinformed 2 2 3 3 4 4 5 5 6  5-5.5 7 5.5 to 6.5 8 6.5 to 7 9 7-8  12 8-9 

It is noted that the initial pH of the reaction medium can be above 11,for example after combining the initial charge of cyclodextrin startingmaterial and base, but prior to addition of alkyl sultone. After analkyl sultone has been added and the reaction commences, however, the pHquickly drops, necessitating addition of base to maintain a basic pH ofabout 8 to about 11.

Once the level of residual unreacted cyclodextrin has reached a desiredlevel, e.g., below 0.5% by weight, during the pH control stage, the pHcan be raised to above 11 for example a level above 12, by addingadditional base to drive the reaction to completion. The pH can be atleast 12 so that the reaction proceeds at a reasonable rate, but not sohigh that unreacted alkyl sultone is hydrolyzed rapidly rather thanreacting with cyclodextrin. During this latter phase of the reaction,additional substitution of the cyclodextrin molecule is effected untilthe pre-determined degree of substitution has been attained. The totalamount of hydroxide added throughout the reaction is typically on theorder of the amount stoichiometrically required plus a 10-20% molarexcess relative to the amount of alkyl sultone employed. The addition ofmore than a 10-20% excess is also feasible. The reaction end point, asnoted above, can be detected by HPLC. A suitable temperature is 65° C.to 95° C. The HPLC system typically employs an anion exchange analyticalcolumn with pulsed amperometric detection (PAD). Elution can be bygradient using a two-solvent system, e.g., Solvent A being 25 mM(millimolar) aqueous sodium hydroxide, and Solvent B being 1 M sodiumnitrate in 250 mM sodium hydroxide.

Once the sulfoalkylation reaction is complete and the tow residualcyclodextrin end point has been reached, additional hydroxide can beadded to destroy and/or degrade any residual sultone. The additionalhydroxide is typically added in an amount of 0.5 to 3 molar equivalentsrelative to cyclodextrin, and the reaction medium is allowed to continueheating at 65° C. to 95° C., typically for 6 hours to 72 hours.

After residual sultone destruction, the resulting crude product can beadditionally treated to produce a final product by being diluted,diafiltered to reduce or rid the product of low molecular weightcomponents such as salts, concentrated, carbon treated, and dried,usually to a level of less than 10% by weight of a cyclodextrin startingmaterial corrected for water content.

The pH is initially monitored to ensure that it remains at about 8 toabout 11 as the sulfoalkyl ether derivatization reaction proceeds. Inthis initial stage, addition of a hydroxide to facilitate thesulfoalkylation can be staged or step-wise. Monitoring the pH of thereaction ensures that the reaction can be controlled such that theentire initial stock of cyclodextrin starting material is essentiallyreacted to the extent of effecting, on average, at least one sulfoalkylsubstitution per cyclodextrin molecule. The entire cyclodextrin reactantis thus consumed at the beginning of the process, so that the level ofresidual (unreacted) cyclodextrin in the crude product is low, relativeto the crude product produced by a process which features initiallycombining the entire stoichiometric or excess amount of base withcyclodextrin and alkyl sultone and allowing the reaction to proceeduncontrolled. After the entire charge of cyclodextrin starting materialhas been partially reacted, the remaining hydroxide can be added todrive the reaction to completion by finishing the sulfoalkylsubstitution to the pre-determined, desired degree. After the initialcharge of cyclodextrin has been consumed in the first pH-controlledphase, the rate of hydroxide addition is not critical. Thus, thehydroxide can he added (e.g., as a solution) continuously or in discretestages. In addition, the pH of the reaction medium should be maintainedabove about 12 so that the rate of reaction is commercially useful.

Initial pH control provides a means for reducing certain by-productsfrom the reaction mixture. For example, an acid is produced as a resultof the sulfoalkylation and the pH of the reaction mixture tends todecrease (i.e., become more acidic) as the reaction proceeds. On onehand, the reaction is maintained basic because if the reaction mediumbecomes acidic, then the reaction will slow considerably or stop.Accordingly, the pH of the reaction medium should be maintained at alevel of at least 8 by adding aqueous hydroxide as needed. On the otherhand, if the pH is allowed to exceed a certain level, for example, a pHgreater than 12, then the reaction can produce a high level ofby-products such as 4-hydroxyalkylsulfonate and bis-sulfoalkyl ether,thus consuming the alkylsultone starting material. By monitoring the pHof the reaction solution and maintaining the pH at 8 to 12, or 8 to 11,the reaction proceeds while producing a relatively low-level ofby-products, and a relatively clean reaction mixture containingrelatively low levels of the aforementioned by-products is provided.

Reference above to a reactant being provided in an amount which is“stoichiometrically sufficient,” and the like, is with respect to theamount of reactant needed to fully derivatize the cyclodextrin ofinterest to a desired degree of substitution. As used herein, an “alkalimetal hydroxide” refers to LiOH, NaOH, KOH, and the like. If it isdesired to produce a product suitable for parenteral administration,then NaOH can he used.

The degree of susbstitution can be controlled by using correspondinglylower or higher amounts of alkyl sultone, depending upon whether a loweror higher degree of substitution is desired. Generally, the degree ofsubstitution that can he achieved is an average of from 4.5 to 7.5, 5.5to 7.5, or 6 to 7.1.

The crude product of the process herein, i.e., the product obtainedfollowing residual alkylsultone destruction, contains a lower level ofresidual cyclodextrin than that produced by a process in which the baseis initially added in a single charge, and is provided as a furtherfeature of the invention. The crude product produced by the process ofthis invention typically contains less than 0.5% by weight residualcyclodextrin, or less than 0.1%. As explained below, the crude productis also advantageous in that it contains very low residual alkylsultonelevels.

Typically, the crude aqueous cyclodextrin product solution obtainedfollowing residual alkylsultone destruction is purified byultrafiltration, a process in which the crude product is contacted witha semipeoneable membrane that passes low molecular weight impuritiesthrough the membrane. The molecular weight of the impurities passedthrough the membrane depends on the molecular weight cut-off for themembrane. For the instant invention, a membrane having a molecularweight cutoff of 1,000 Daltons (“Da”) is typically employed.Diafiltrations and/or ultrafiltrations can be conducted with filtrationmembranes having a molecular weight cut-off of 500 Da to 2,000 Da, 500Da to 1,500 Da, 750 Da to 1,250 Da, or 900 Da to 1,100 Da, or about1,000 Da. The desired product which is in the retentate is then furthertreated with activated carbon to substantially remove drug-degradingimpurities. The crude aqueous cyclodextrin product solution (i.e.,obtained after residual alkyl sultone destruction but beforepurification) is advantageous in that it contains less than 2 ppmresidual alkyl sultone based on the weight of the solution, less than 1ppm, less than 250 ppb. The crude solution can also contain essentiallyno residual alkylsultone.

A final, commercial product can be isolated at this point by, e.g.,filtration to remove the activated carbon, followed by evaporation ofthe water (via, e.g., distillation, spray dying, lyophilization, and thelike). The final product produced by the instant inventionadvantageously contains very low residual levels of alkyl sultone, e.g.,less than 2 ppm based on the weight of the dry (i.e., containing lessthan 10% by weight water) final product, less than I ppm, less than 250ppb, or essentially no residual alkyl sultone. The final productcontaining less than 250 ppb of alkyl sultone is accordingly provided asan additional feature of the invention. The alkyl sultone is reducedfollowing completion of the sulfoalkylation to the desired degree ofsubstitution by an alkaline hydrolysis treatment as previouslydescribed, i.e., by adding extra hydroxide solution in an amount andunder conditions sufficient to reduce the amount of unreacted sultone inthe dry product to the desired level below 2 ppm, less than 1 ppm, orless than 250 ppb.

Activated carbon suitable for use in the process of the presentinvention can be phosphate-free, and can be powder or granular, or asuspension or slurry produced therefrom. Generally, phosphate-freeactivated carbon is a carbon that was not activated using, or otherwiseexposed to, phosphoric acid.

A wide variety of activated carbon is available. For example,Norit-Americas commercializes over 150 different grades and varieties ofactivated carbon under trademarks such as DARCO™, HYDRODARCO®, NORIT®,BENTONORIT®, PETRODARCO®, and SORBONORIT®. The carbons differ inparticle size, application, method of activation, and utility. Forexample, some activated carbons are optimized for color and/or flavorremoval. Other activated carbons are optimized for removal of protein,mineral, and/or amino acid moieties, or for clarifying solutions.

Activated carbons suitable for use according to the present inventioninclude, but arc not limited to: DARCO®, 4×12, 12×20, or 20×40 granularfrom lignite, steam activated (Norit Americas, Inc., Amersfoort, Nebr.);DARCO® S 51 HF (from lignite, steam activated, powder); and SHIRASAGI®DC-32 powered or granular carbon from wood, zinc chloride activated(Takeda Chemical Industries, Ltd., Osaka, JP).

Carbon that is activated with phosphoric acid, as used in the prior artfor purifying sulfoalkyl ether cyclodextrins, is generally unsuitablefor use with the present invention, and includes: DARCO® KB-G, DARCO®KB-B and DARCO® KB-WJ, as well as NORIT® CASP and NORIT® CN1.

The loading ratio of activated carbon ultimately depends upon the amountor concentration of SAE-CD, color-forming agents, and drug-degradingagents in solution as well as the physical properties of the activatedcarbon used. In general, the weight ratio of a cyclodextrin to activatedcarbon is 5:1 to 10:1, 6:1 to 9:1, 7:1 to 9:1, 8:1 to 9:1, 8.3:1 to8.5:1, 8.4:1 to 8.5:1, or 8.44:1 by weight per treatment cycle.

As used herein, “treatment cycle” refers to a contacting a predeterminedamount of a cyclodextrin composition with a predetermined amount ofactivated carbon. A treatment cycle can be performed as a singletreatment or as a multiple (recycling) pass-through treatment.

The Examples contained herein detail procedures used to evaluate andcompare the efficiency of different grades, lots, sources, and types ofactivated carbon in removing the one or more drug-degrading componentsand one or more color-forming components present in an in-process milieuor solution of SAE-CD. In general, an in process milieu or solution istreated with activated carbon and agitation for 120 min. If a loose,particulate, or powdered form of activated carbon is used, it can beremoved by filtration of a liquid containing the carbon through afiltration medium to provide the clarified solution.

The filtration membrane can include nylon, TEFLON®, PVDF or anothercompatible material. The pore size of the filtration membrane can bevaried as needed according to the particle size or molecular weight ofspecies being separated from the SAE-CD in a solution containing thesame.

The Examples herein detail procedures for conducting one or moreseparations and/or purifications on an aqueous reaction milieu of thepresent invention. A reaction solution is diluted with aqueous solutionand subjected to diafiltration during which the volume of the retentateis maintained substantially constant. The diafiltration can be conductedover a 1,000 Da filter such that one or more unwanted components passthrough the filter but the majority of the sulfoalkyl ether present inthe SAE-CD composition is retained in the retentate rather than passingthrough with the filtrate. The ultrafiltration is then conducted byallowing the volume of the retentate to decrease thereby concentratingthe retentate. A filter having a molecular weight cut-off of about 1,000Da can also be used for the ultrafiltraton. The retentate comprises theSAE-CD, which can then be treated with activated carbon as describedherein.

The one or more unwanted components can include, but are not limited to,low molecular weight impurities (i.e., impurities having a molecularweight of about 500 Da or less), water-soluble and/or water-insolubleions (i.e., salts), hydrolyzed sulfoalkylating agent,5-(hydroxymethyl)-2-furaldehyde, unreacted cyclodextrin startingmaterial, degraded cyclodextrin species (e.g., degraded and/orring-opened species formed from unreacted cyclodextrin, partiallyreacted cyclodextrin, and/or SAE-CD), unreacted sulfoalkylating agent(e.g., 1,4-butane sultone), and combinations thereof.

In some embodiments, the compositions of the present invention aresubstantially free of one or more drug degrading agents. The presence ofone or more drug degrading agents can be determined, inter alia, byUV/visible (“UV/vis”) spectrophotometry. As used herein, a “drugdegrading agent” refers to a species, moiety, and the like, thatdegrades an active component in aqueous solution. In some embodiments, adrug-degrading species has an absorption in the UV/visible region of thespectrum, for example, an absorption maximum at a wavelength of 245 nmto 270 nm.

Not being bound by any particular theory, a drug-degrading agent,species, or moiety can include one or more low-molecular weight species(e.g., a species having a molecular weight less than 1,000 Da), such as,but not limited to a species generated as a side-product and/ordecomposition product in the reaction mixture. As such, drug-degradingspecies include, but are not limited to, a glycosidic moiety, aring-opened cyclodextrin species, a reducing sugar, a glucosedegradation product (e.g., 3,4-dideoxyglucosone-3-ene,carbonyl-containing degradants such as 2-furaldehyde,5-hydroxymethyl-2-furaldehyde and the like), and combinations thereof.

By “complexed” is meant “being part of a clathrate or inclusion complexwith,” i.e., a “complexed” therapeutic agent is part of a clathrate orinclusion complex with a sulfoalkyl ether cyclodextrin. The term “majorportion” refers to 50% or greater, by weight, or on a molar basis. Thus,a formulation according to the present invention can contain an activeagent of which more than about 50% by weight is complexed with asulfoalkyl ether cyclodextrin. The actual percentage of active agentthat is complexed will vary according to the complexation equilibriumbinding constant characterizing the complexation of a specificcyclodextrin with a specific active agent. The invention also includesembodiments wherein the active agent is not complexed with thecyclodextrin or in which only a minor portion of the active agent iscomplexed with the sulfoalkyl ether cyclodextrin. It should be notedthat a sulfoalkyl ether cyclodextrin, can form one or more ionic bondswith a positively charged compound. This ionic association can occurregardless of whether the positively charged compound is complexed withthe cyclodextrin by inclusion complexation.

Among other uses, a SAE-CD composition of the present invention can beused to solubilize and/or stabilize a variety of different materials andto prepare formulations for particular applications. The present SAE-CDcomposition can provide enhanced solubility and/or enhanced chemical,thermochemical, hydrolytic and/or photochemical stability of otheringredients in a composition. For example, a SAE-CD composition can beused to stabilize an active agent in an aqueous medium. A SAE-CDcomposition can also be used to increase the solubility of an activeagent in an aqueous medium.

The SAE-CD composition of the present invention includes one or moreactive agents. The one or more active agents included in the compositionof the present invention can possess a wide range of water solubility,bioavailability and hydrophilicity. Active agents to which the presentinvention is particularly suitable include water insoluble, poorlywater-soluble, slightly water-soluble, moderately water-soluble,water-soluble, very water-soluble, hydrophobic, and/or hydrophilictherapeutic agents. It will be understood by a person of ordinary skillin the art one or more active agents present in a composition of thepresent invention is independently selected at each occurrence from anyknown active agent and from those disclosed herein. It is not necessarythat the one or more active agents form a complex with the sulfoalkylether cyclodextrin, or form an ionic association with the sulfoalkylether cyclodextrin.

Active agents generally include physiologically or pharmacologicallyactive substances that produce a systemic or localized effect or effectson animals and human beings. Active agents also include pesticides,herbicides, insecticides, antioxidants, plant growth instigators,sterilization agents, catalysts, chemical reagents, food products,nutrients, cosmetics, vitamins, sterility inhibitors, fertilityinstigators, microorganisms, flavoring agents, sweeteners, cleansingagents, pharmaceutically effective active agents, and other suchcompounds for pharmaceutical, veterinary, horticultural, household,food, culinary, agricultural, cosmetic, industrial, cleaning,confectionery and flavoring applications. The active agent can bepresent in its neutral, ionic, salt, basic, acidic, natural, synthetic,diastereomeric, isomeric, enantiomerically pure, racemic, hydrate,chelate, derivative, analog, or other common form.

Representative pharmaceutically effective active agents includenutrients and nutritional agents, hematological agents, endocrine andmetabolic agents, cardiovascular agents, renal and genitourinary agents,respiratory agents, central nervous system agents, gastrointestinalagents, anti-fungal agents, anti-infective agents, biologic andimmunological agents, dermatological agents, ophthalmic agents,antineoplastic agents, and diagnostic agents. Exemplary nutrients andnutritional agents include as minerals, trace elements, amino acids,lipotropic agents, enzymes and chelating agents. Exemplary hematologicalagents include hematopoietic agents, antiplatelet agents,anticoagulants, coumarin and indandione derivatives, coagulants,thrombolytic agents, antisickling agents, hemorrheologic agents,antihemophilic agents, hemostatics, plasma expanders and hemin.Exemplary endocrine and metabolic agents include sex hormones,uterine-active agents, bisphosphonates, antidiabetic agents, glucoseelevating agents, corticosteroids, adrenocortical steroids, parathyroidhormone, thyroid drugs, growth hormones, posterior pituitary hormones,octreotide acetate, imiglucerase, calcitonin-salmon, sodiumphenylbutyrate, betaine anhydrous, cysteamine bitartrate, sodiumbenzoate and sodium phenylacetate, bromocriptine mesylate, cabergoline,agents for gout, and antidotes. Antifunal agents suitable for use withthe SAE-CD composition of the present invention include, but are notlimited to, posaconazole, voriconazole, clotrimazole, ketoconazole,oxiconazole, sertaconazole, tetconazole, fluconazole, itraconazole andmiconazole. Antipsychotic agents suitable for use with the SAE-CDcomposition of the present invention include, but are not limited to,clozapine, prochlorperazine, haloperidol, thioridazine, thiothixene,risperidone, trifluoperazine hydrochloride, chlorpromazine,aripiprazole, loxapine, loxitane, olanzapine, quetiapine furnarate,risperidone and ziprasidone

Exemplary cardiovascular agents include nootropic agents, antiarrhythmicagents, calcium channel blocking agents, vasodilators,antiadrenergics/sympatholytics, renin angiotensin system antagonists,antihypertensive agent combinations, agents for pheochromocytoma, agentsfor hypertensive emergencies, antihyperlipidemic agents,antihyperlipidemic combination products, vasopressors used in shock,potassium removing resins, edetate disodium, cardioplegic solutions,agents for patent ductus arteriosus, and sclerosing agents. Exemplaryrenal and genitourinary agents include interstitial cystitis agents,cellulose sodium phosphate, anti-impotence agents, acetohydroxamic acid(aha), genitourinary irrigants, cystine-depleting agents, urinaryalkalinizers, urinary acidifiers, anticholinergics, urinarycholinergics, polymeric phosphate binders, vaginal preparations, anddiuretics. Exemplary respiratory agents include bronchodilators,leukotriene receptor antagonists, leukotriene formation inhibitors,respiratory inhalant products, nasal decongestants, respiratory enzymes,lung surfactants, antihistamines, nonnarcotic antitussives, andexpectorants. Exemplary central nervous system agents include CNSstimulants, narcotic agonist analgesics, narcotic agonist-antagonistanalgesics, central analgesics, acetaminophen, salicylates, nonnarcoticanalgesics, nonsteroidal anti-inflammatory agents, agents for migraine,antiemetic/antivertigo agents, antianxiety agents, antidepressants,antipsychotic agents, cholinesterase inhibitors, nonbarbituratesedatives and hypnotics, nonprescription steep aids, barbituratesedatives and hypnotics, general anesthetics, injectable localanesthetics, anticonvulsants, muscle relaxants, antiparkinson agents,adenosine phosphate, cholinergic muscle stimulants, disulfuram, smokingdeterrents, riluzole, hyaluronic acid derivatives, and botulinum toxins.Exemplary gastrointestinal agents including H pylori agents, histamineH2 antagonists, proton pump inhibitors, sucralfate, prostaglandins,antacids, gastrointestinal anticholinergics/antispasmodics, mesalamine,olsalazine sodium, balsalazide disodium, sulfasalazine, celecoxib,infliximab, tegaserod maleate, laxatives, antidiarrheals,antiflatulents, lipase inhibitors, GI stimulants, digestive enzymes,gastric acidifiers, hydrocholeretics, gallstone solubilizing agents,mouth and throat products, systemic deodorizers, and anorectalpreparations. Exemplary anti-infective agents including penicillins,cephalosporins and related antibiotics, carbapenem, monobactams,chloramphenicol, quinolones, fluoroquinolones, tetracyclines,inacrolides, spectinomycin, streptogramins, vancomycin, oxalodinones,lincosamides, oral and parenteral aminoglycosides, colistimethatesodium, polymyxin b sulfate, bacitracin, metronidazole, sulfonamides,nitrofurans, methenamines, folate antagonists, anti fungal agents,antimalarial preparations, antituberculosis agents, amebicides,antiviral agents, antiretroviral agents, leprostatics, antiprotozoals,anthelmintics, and cdc, anti-infective agents. Exemplary biologic andimmunological agents including immune globulins, monoclonal antibodyagents, antivenins, agents for active immunization, allergenic extracts,immunologic agents, and antirheumatic agents. Exemplary dermatologicalagents include topical antihistamine preparations, topicalanti-infectives, anti-inflammatory agents, anti-psoriatic agents,antiseborrheic products, arnica, astringents, cleansers, capsaicin,destructive agents, drying agents, enzyme preparations, topicalimmunomodulators, keratolytic agents, liver derivative complex, topicallocal anesthetics, minoxidil, eflornithine hydrochloride,photochemotherapy agents, pigment agents, topical poison ivy products,topical pyrimidine antagonist, pyrithione zinc, retinoids, rexinoids,scabicides/pediculicides, wound healing agents, emollients, protectants,sunscreens, ointment and lotion bases, rubs and liniments, dressings andgranules, and physiological irrigating solutions. Exemplary ophthalmicagents include agents for glaucoma, mast cell stabilizers, ophthalmicantiseptics, ophthalmic phototherapy agents, ocular lubricants,artificial tears, ophthalmic hyperosmolar preparations, and contact lensproducts. Exemplary antineoplastic agents include alkylating agents,antimetabolites, antimitotic agents, epipodophyllotoxins, antibiotics,hormones, enzymes, radiopharmaceuticals, platinum coordination complex,anthracenedione, substituted ureas, methylhydrazine derivatives,imidazotetrazine derivatives, cytoprotective agents, dna topoisomeraseinhibitors, biological response modifiers, retinoids, rexinoids,monoclonal antibodies, protein-tyrosine kinase inhibitors, porfimersodium, mitotane (o, p′-ddd), and arsenic trioxide. Exemplary diagnosticagents include in vivo diagnostic aids, in vivo diagnostic biologicals,and radiopaque agents.

The above-listed active agents should not be considered exhaustive andis merely exemplary of the many embodiments considered within the scopeof the invention. Many other active agents can be administered with theformulation of the present invention.

A formulation of the invention can be used to deliver two or moredifferent active agents. Particular combinations of active agents can beprovided in a formulation of the invention. Some combinations of activeagents include: 1) a first drug from a first therapeutic class and adifferent second drug from the same therapeutic class; 2) a first drugfrom a first therapeutic class and a different second drug from adifferent therapeutic class; 3) a first drug having a first type ofbiological activity and a different second drug having about the samebiological activity; and 4) a first drug having a first type ofbiological activity and a different second drug having a differentsecond type of biological activity. Exemplary combinations of activeagents are described herein.

An active agent contained within a formulation of the invention can bepresent as its pharmaceutically acceptable salt. As used herein,“pharmaceutically acceptable salt” refers to derivatives of thedisclosed compounds wherein the active agent is modified by reacting itwith an acid and/or base as needed to form an ionically bound pair.Examples of pharmaceutically acceptable salts include conventionalnon-toxic salts or the quaternary ammonium salts of a compound formed,for example, from non-toxic inorganic or organic acids. Suitablenon-toxic salts include those derived from inorganic acids such ashydrochloric, hydrobromic, sulfuric, sulfonic, sulfamic, phosphoric,nitric and others known to those of ordinary skill in the art. The saltsprepared from organic acids such as amino acids, acetic, propionic,succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic,pamoic, maleic, hydroxyrnaleic, phenylacetic, glutamic, benzoic,salicylic, sulfanilic, 2-acetoxyben.zoic, fumaric, toluenesultbnic,methanesulfonic, ethane disulfonic, oxalic, iscthionic, and others knownto those of ordinary skill in the art. Pharmaceutically acceptable saltssuitable for use with the present invention can be prepared using anactive agent that includes a basic or acidic group by conventionalchemical methods. Suitable addition salts are found in Remington'sPharmaceutical Sciences (17th ed., Mack Publishing Co., Easton, Pa.,1985), the relevant disclosure of which is hereby incorporated byreference in its entirety.

The present invention is also directed to a method for stabilizing anactive agent, the method comprising: providing a SAE-CD compositioncomprising a sulfoalkyl ether cyclodextrin and less than 100 ppm of aphosphate, wherein the SAE-CD composition has an absorption of less than0.5 A.U. due to a drug-degrading agent, as determined by UV/visspectrophotometry at a wavelength of 245 nm to 270 nm for an aqueoussolution containing 300 mg of the SAE-CD composition per ml. of solutionin a cell having a 1 cm path length; and combining the SAE-CDcomposition with an active agent.

The method of stabilizing an active agent can be performed wherein thecomposition comprising one or more active agents and a SAE-CDcomposition comprising a sulfoalkyl ether cyclodextrin and less than 100ppm of a phosphate is present as a dry solution, a wet solution, aninhalable composition, a parenteral composition, a solid solution, asolid mixture, a granulate, a gel, and other active agent compositionsknown to persons of ordinary skill in the art.

In some embodiments, the method of stabilizing an active agent providesabout 2% or less, about 1.5% or less, about 1% or less, or about 0.5% orless of a drug-degradation impurity after the composition comprising oneor more active agents and a SAE-CD composition comprising a sulfoalkylether cyclodextrin and less than 100 ppm of a phosphate is maintained ata temperature of about 80° C. for a period of about 120 minutes.

Similarly, in some embodiments, the method of stabilizing an activeagent provides about an active agent assay of about 98% or more, about98.5% or more, about 99% or more, or about 99.5% or more of the activeagent after the composition comprising one or more active agents and aSAE-CD composition comprising a sulfoalkyl ether cyclodextrin and lessthan 100 ppm of a phosphate is maintained at a temperature of about 80°C. for a period of about 120 minutes.

Generally, the SAE-CD is present in an amount sufficient to stabilizethe active agent. An amount sufficient can be a molar ratio of about0.1:1 to about 10:1, about 0.5:1 to about 10:1, about 0.8:1 to about10:1, or about 1:1 to about 5:1 (SAE-CD:active agent).

A cyclodextrin in the combination composition need not bind with anothermaterial, such as an active agent, present in a formulation containingit. However, if a cyclodextrin binds with another material, such a bondcan be formed as a result of an inclusion complexation, an ion pairformation, a hydrogen bond, and/or a Van der Waals interaction.

An anionic derivatized cyclodextrin can complex or otherwise bind withan acid-ionizable agent. As used herein, the term acid-ionizable agentis taken to mean any compound that becomes or is ionized in the presenceof an acid. An acid-ionizable agent comprises at least oneacid-ionizable functional group that becomes ionized when exposed toacid or when placed in an acidic, medium. Exemplary acid-ionizablefunctional groups include a primary amine, secondary amine, tertiaryamine, quaternary amine, aromatic amine, unsaturated amine, primarythiol, secondary thiol, sulfonium, hydroxyl, enol and others known tothose of ordinary skill in the chemical arts.

The degree to which an acid-ionizable agent is bound by non-covalentionic binding versus inclusion complexation formation can be determinedspectrometrically using methods such as ¹H-NMR, ¹³C-NMR, or circulardichroism, for example, and by analysis of the phase solubility data forthe acid-ionizable agent and anionic derivatized cyclodextrin. Theartisan of ordinary skill in the art will be able to use theseconventional methods to approximate the amount of each type of bindingthat is occurring in solution to determine whether or not bindingbetween the species is occurring predominantly by non-covalent ionicbinding or inclusion complex formation. Under conditions wherenon-covalent ionic bonding predominates over inclusion complexformation, the amount of inclusion complex formation, measured by NMR orcircular dichroism, will be reduced even though the phase solubilitydata indicates significant binding between the species under thoseconditions; moreover, the intrinsic solubility of the acid-ionizableagent, as determined from the phase solubility data, will generally behigher than expected under those conditions.

As used herein, the term “non-covalent ionic bond” refers to a bondformed between an anionic species and a cationic species. A bond isnon-covalent such that the two species together form a salt or ion pair.An anionic derivatized cyclodextrin provides the anionic species of theion pair and the acid-ionizable agent provides the cationic species ofthe ion pair. Since an anionic derivatized cyclodextrin is multi-valent,a SAE-CD can form an ion pair with one or more acid-ionizable orotherwise cationic agents.

A liquid formulation of the invention can be converted to a solidformulation for reconstitution. A reconstitutable solid compositionaccording to the invention comprises an active agent, a derivatizedcyclodextrin and optionally at least one other pharmaceutical excipient.A reconstitutable composition can be reconstituted with an aqueousliquid to form a liquid formulation that is preserved. The compositioncan comprise an admixture (minimal to no presence of an inclusioncomplex) of a solid derivatized cyclodextrin and an activeagent-containing solid and optionally at least one solid pharmaceuticalexcipient, such that a major portion of the active agent is notcomplexed with the derivatized cyclodextrin prior to reconstitution.Alternatively, the composition can comprise a solid mixture of aderivatized cyclodextrin and an active agent, wherein a major portion ofthe active agent is complexed with the derivatized cyclodextrin prior toreconstitution. A reconstitutable solid composition can also comprise aderivatized cyclodextrin and an active agent where substantially all orat least a major portion of the active agent is complexed with thederivatized cyclodextrin.

A reconstitutable solid composition can be prepared according to any ofthe following processes. A liquid formulation of the invention is firstprepared, then a solid is formed by lyophilization (freeze-drying),spray-drying, spray freeze-drying, antisolvent precipitation, asepticspray drying, various processes utilizing supercritical or nearsupercntical fluids, or other methods known to those of ordinary skill nthe art to make a solid for reconstitution.

A liquid vehicle included in a formulation of the invention can comprisean aqueous liquid carrier (e.g., water), an aqueous alcohol, an aqueousorganic solvent, a non-aqueous liquid carrier, and combinations thereof.

The formulation of the present invention can include one or morepharmaceutical excipients selected from the group consisting of aconventional preservative, antifoaming agent, antioxidant, bufferingagent, acidifying agent, alkalizing agent, bulking agent, colorant,complexation-enhancing agent, cryoprotectant, electrolyte, glucose,emulsifying agent, oil, plasticizer, solubility-enhancing agent,stabilizer, tonicity modifier, flavors, sweeteners, adsorbents,antiadherent, binder, diluent, direct compression excipient,disintegrant, glidant, lubricant, opaquant, polishing agent, complexingagents, fragrances, other excipients known by those of ordinary skill inthe art for use in formulations, and a combination thereof.

As used herein, the term “adsorbent” is intended to mean an agentcapable of holding other molecules onto its surface by physical orchemical (chemisorption) means. Such compounds include, by way ofexample and without limitation, powdered and activated charcoal andother materials known to one of ordinary skill in the art.

As used herein, the term “alkalizing agent” is intended to mean acompound used to provide alkaline medium for product stability. Suchcompounds include, by way of example and without limitation, ammoniasolution, ammonium carbonate, diethanolamme, monoethanolamine, potassiumhydroxide, sodium borate, sodium carbonate, sodium bicarbonate, sodiumhydroxide, triethanolamine, diethanolamine, organic airline base,alkaline amino acids and trolamine and others known to those of ordinaryskill in the art.

As used herein, the term “acidifying agent” is intended to mean acompound used. to provide an acidic medium for product stability. Suchcompounds include, by way of example and without limitation, aceticacid, acidic amino acids, citric acid, fumaric acid and other α-hydroxyacids, hydrochloric acid, ascorbic acid, phosphoric acid, sulfuric acid,tartaric acid and nitric acid and others known to those of ordinaryskill in the art.

As used herein, the term “antiadherent” is intended to mean an agentthat prevents the sticking of solid dosage formulation ingredients topunches and dies in a tableting machine during production. Suchcompounds include, by way of example and without limitation, magnesiumstearate, talc, calcium stearate, glyceryl behenate, polyethyleneglycol, hydrogenated vegetable oil, ineral oil, stearic acid and othermaterials known to one of ordinary skill in the art.

As used herein, the term “binder” is intended to mean a substance usedto cause adhesion of powder particles in solid dosage formulations. Suchcompounds include, by way of example and without limitation, acacia,alginic acid, carboxymethylcellulose sodium, poly(vinylpyrrolidone), acompressible sugar, ethylcellulose, gelatin, liquid glucose,methylcellulose, povidone and pregelatinized starch and other materialsknown to one of ordinary skill in the art.

When needed, binders can also be included in the dosage forms. Exemplarybinders include acacia, tragacanth, gelatin, starch, cellulose materialssuch as methyl cellulose and sodium carboxymethylcellulose, alginicacids and salts thereof, polyethylene glycol, guar gum, polysaccharide,bentonites, sugars, invert sugars, poloxamers (PLURONIC™ F68, PLURONIC™F127), collagen, albumin, gelatin, cellulosics in non-aqueous solvents,combinations thereof and others known to those of ordinary skill in theart. Other binders include, for example, polypropylene glycol,polyoxyethylene-polypropylene copolymer, polyethylene ester,polyethylene sorbitan ester, polyethylene oxide, combinations thereofand other materials known to one of ordinary skill in the art.

As used herein, a conventional preservative is a compound used to atleast reduce the rate at which bioburden increases, but maintainsbioburden steady or reduces bioburden after contamination. Suchcompounds include, by way of example and without limitation,benzalkonium chloride, benzethonium chloride, benzoic acid, benzylalcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethylalcohol, phenylmercuric nitrate, phenylmercuric acetate, thimerosal,metacresol, myristylgamma picolinium chloride, potassium benzoate,potassium sorbate, sodium benzoate, sodium propionate, sorbic acid,thymol, and methyl, ethyl, propyl or butyl parabens and others known tothose of ordinary skill in the art. It is understood that somepreservatives can interact with the cyclodextrin derivative thusreducing the preservative effectiveness. Nevertheless, by adjusting thechoice of preservative and the concentrations of preservative and thecyclodextrin derivative adequately preserved formulations can be found.

As used herein, the term “diluent” or “filler” is intended to mean aninert substance used as a filler to create the desired bulk, flowproperties, and compression characteristics in the preparation of aliquid or solid dosage form. Such compounds include, by way of exampleand without limitation, a liquid vehicle (e.g., water, alcohol,solvents, and the like), dibasic calcium phosphate, kaolin, lactose,dextrose, magnesium carbonate, sucrose, mannitol, microcrystallinecellulose, powdered cellulose, precipitated calcium carbonate, sorbitol,and starch and other materials known to one of ordinary skill in theart.

As used herein, the term “direct compression excipient” is intended tomean a compound used in compressed solid dosage forms. Such compoundsinclude, by way of example and without limitation, dibasic calciumphosphate, and other materials known to one of ordinary skill in theart.

As used herein, the term “antioxidant” is intended to mean an agent thatinhibits oxidation and thus is used to prevent the deterioration ofpreparations by the oxidative process. Such compounds include, by way ofexample and without limitation, acetone, potassium metabisulfite,potassium sulfite, ascorbic acid, ascorbyl palmitate, citric acid,butylated hydroxyanisole, butylated hydroxytoluene, hypophophorous acid,monothioglycerol, propyl gallate, sodium ascorbate, sodium citrate,sodium sulfide, sodium sulfite, sodium bisulfite, sodium formaldehydesulfoxylate, thioglycolic acid, EDTA, pentetate, and sodiummetabisulfite and others known to those of ordinary skill in the art.

As used herein, the term “buffering agent” is intended to mean acompound. used to resist change in pH upon dilution or addition of acidor alkali. Such compounds include, by way of example and withoutlimitation, acetic acid, sodium acetate, adipic acid, benzoic acid,sodium benzoate, boric acid, sodium borate, citric acid, glycine, maleicacid, monobasic sodium phosphate, dibasic sodium phosphate,4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, lactic acid,tartaric acid, potassium metaphosphate, potassium phosphate, monobasicsodium acetate, sodium bicarbonate, tris, sodium tartrate and sodiumcitrate anhydrous and dihydrate and others known to those of ordinaryskill in the art.

A complexation-enhancing agent can be added to a formulation of theinvention. When such an agent is present, the ratio ofcyclodextrin/active agent can be changed. A complexation-enhancing agentis a compound, or compounds, that enhance(s) the complexation of theactive agent with the cyclodextrin. Suitable complexation enhancingagents include one or more pharmacologically inert water-solublepolymers, hydroxy acids, and other organic compounds typically used inpreserved formulations to enhance the complexation of a particular agentwith cyclodextrins.

Hydrophilic polymers can be used as complexation-enhancing, enhancingand/or water activity reducing agents to improve the performance offormulations containing a CD-based preservative. Loftsson has discloseda number of polymers suitable for combined use with a cyclodextrin(underivatized or derivatized) to enhance the performance and/orproperties of the cyclodextrin. Suitable polymers are disclosed inPharmazie 56:746 (2001); Int. J. Pharm. 212:29 (2001); Cyclodextrin:From Basic Research to Market, 10th Inn Cyclodextrin Symposium, AnnArbor, Mich., US, May 21-24, p. 10-15 (2000); PCT Intl Pub. No. WO99/42111; Pharmazie 53:733 (1998); Pharm. Technol. Ear. 9:26 (1997); J.Pharm. Sci. 85:1017 (1996); European Patent Appl. No. 0 579 435; Proc.of the 9th int'l Symposium on Cyclodextrins, Santiago de Comostela, ES,May 31-June 3, 1998, pp. 261-264 (1999); S.T.P. Pharma Sciences 9:237(1999); Amer. Chem. Soc. Symposium Series 737 (PolysaccharideApplications):24-45 (1999); Pharma. Res. 15:1696 (1998); Drug Dev.Pharm. 24:365 (1998); Int. J. Pharm. 163:115 (1998); Book of Abstracts,216th Amer. Chem. Soc. Nat'l. Meeting, Boston, Augusrt 23-27 CELL-016(1998); J. Controlled Release 44:95 (1997); Pharm. Res. (1997) 14(11),S203; Invest. Ophthahnol. Vis. Sci. 37:1199 (1996); Proc. of the 23rdInt'l Symposium on Controlled Release of Bioactive Materials 453-454(1996); Drug Dev. Pharm. 22:401 (1996); Proc. of the 8th Int'l Symposiumon Cyclodextrins, Budapest, HU, March 31-Apr. 2, 1996, pp. 373-376(1996); Pharma. Sci. 2:277 (1996); Eur. J. Pharm. Sci. 4S:S144 (1996);3rd Eur. Congress of Pharma. Sci. Edinburgh, Scotland, UK Sep. 15-17,1996; Pharmazie 51:39 (1996); Eur. Pharm. Sci. 45:S143 (1996); U.S. Pat.Nos. 5,472,954 and 5,324,718; Int. J. Pharm. 126:73 (1995); Abstracts ofPapers of the Amer. Chem. Soc. 209:33-CELL (1995); Eur. J Pharm. Sci.2:297 (1994); Pharm. Res. 11:S225 (1994); Int. J. Pharm. 104:181 (1994);and Int. J. Pharm. 110:169 (1994), the entire disclosures of which arehereby incorporated by reference in their entirety.

Other suitable polymers are well-known excipients commonly used in thefield of pharmaceutical forEtiulations and are included in, for example,Remington's Pharmaceutical Sciences, 18th ed., pp. 291-294, Gennaro(editor), Mack Publishing Co., Easton, Pa. (1990); A. Martin et al.,Physical Pharmacy. Physical Chemical Principles in PharmaceuticalSciences, 3d ed., pp. 592-638 (Lea & Febinger, Philadelphia, Pa. (1983);A. T. Florence et al., Physicochemical Principles of Pharmacy, 2d ed.,pp. 281-334, MacMillan Press, London, UK (1988), the disclosures ofwhich are incorporated herein by reference in their entirety. Stillother suitable polymers include water-soluble natural polymers,water-soluble semi-synthetic polymers (such as the water-solublederivatives of cellulose) and water-soluble synthetic polymers. Thenatural polymers include polysaccharides such as inulin, pectin, alginderivatives (e.g. sodium alginate) and agar, and polypeptides such ascasein and gelatin. The semi-synthetic polymers include cellulosederivatives such as methylcellulose, hydmxyethyleellulose,hydroxypropylcellulose, their mixed ethers such ashydroxypropylmethylcellulose and other mixed ethers such ashydroxyethyl-ethylcellulose and hydroxympylethylcellulose,hydroxypropylmethylcellulose phthalate and carboxymethylcellulose andits salts, especially sodium carboxymethylcellulose. The syntheticpolymers include polyoxyethylene derivatives (polyethylene glycols) andpolyvinyl derivatives (polyvinyl alcohol, polyvinylpyrrolidone andpolystyrene sulfonate) and various copolymers of acrylic acid (e.g.carbomer). Other natural, semi-synthetic and synthetic polymers notnamed here which meet the criteria of water solubility, pharmaceuticalacceptability and pharmacological inactivity are likewise considered tobe within the ambit of the present invention.

As used herein, a fragrance is a relatively volatile substance orcombination of substances that produces a detectable aroma, odor orscent. Exemplary fragrances include those generally accepted as safe bythe U.S. Food and. Drug Administration.

As used herein, the term “glidant” is intended to mean an agent used insolid dosage formulations to promote flowability of the solid mass. Suchcompounds include, by way of example and without limitation, colloidalsilica, cornstarch, talc, calcium silicate, magnesium silicate,colloidal silicon, tribasic, calcium phosphate, silicon hydrogel andother materials known to one of ordinary skill in the art.

As used herein, the term “lubricant” is intended to mean a substanceused in solid dosage formulations to reduce friction during compression.Such compounds include, by way of example and without limitation,calcium stearate, magnesium stearate, polyethylene glycol, talc, mineraloil, stearic acid, and zinc stearate and other materials known to one ofordinary skill in the art.

As used herein, the term “opaquant” is intended to mean a compound usedto render a coating opaque. An opaquant can be used alone or incombination with a colorant. Such compounds include, by way of exampleand without limitation, titanium dioxide, talc and other materials knownto one of ordinary skill in the art.

As used herein, the term “polishing agent” is intended to mean acompound used to impart an attractive sheen to solid dosage forms. Suchcompounds include, by way of example and without limitation, carnaubawax, white wax and other materials known to one of ordinary skill in theart.

As used herein, the term “disintegrant” is intended to mean a compoundused in solid dosage forms to promote the disruption of the solid massinto smaller particles which are more readily dispersed or dissolved.Exemplary disintegrants include, by way of example and withoutlimitation, starches such as corn starch, potato starch, pre-gelatinizedand modified starches thereof, sweeteners, clays, bentonite,microcrystalline cellulose (e.g., AVICEL®), carboxymethylcellulosecalcium, croscarmcllose sodium, alginic acid, sodium alginate, cellulosepolacrilin potassium (e.g., AMBERLITE®), alginates, sodium starchglycolate, gums, agar, guar, locust bean, karaya, pectin, tragacanth,crospovidone and other materials known to one of ordinary skill in theart.

As used herein, the term “stabilizer” is intended to mean a compoundused to stabilize the therapeutic agent against physical, chemical, orbiochemical process which would reduce the therapeutic activity of theagent. Suitable stabilizers include, by way of example and withoutlimitation, albumin, sialic acid, creatinine, glycine and other aminoacids, niacinamide, sodium acetyltryptophonate, zinc oxide, sucrose,glucose, lactose, sorbitol, mannitol, glycerol, polyethylene glycols,sodium caprylate and sodium saccharin and other known to those ofordinary skill in the art.

As used herein, the term “tonicity modifier” is intended to mean acompound or compounds that can be used to adjust the tonicity of theliquid formulation. Suitable tonicity modifiers include glycerin,lactose, mannitol, dextrose, sodium chloride, sodium sulfate, sorbitol,trehalose and others known to those of ordinary skill in the art. In oneembodiment, the tonicity of the liquid formulation approximates thetonicity of blood or plasma,

As used herein, the term “antifoaming agent” is intended to mean acompound or compounds that prevents or reduces the amount of foamingthat forms on the surface of the liquid formulation. Suitableantifoaming agents include dimethicone, simethicone, octoxynol andothers known to those of ordinary skill in the art.

As used herein, the term “bulking agent” is intended to mean a compoundused to add bulk to the solid product and/or assist in the control ofthe properties of the formulation during lyophilization. Such compoundsinclude, by way of example and without limitation, dextran, trehalose,sucrose, polyvinylpyrrolidone, lactose, inositol, sorbitol,dimethylsulfoxide, glycerol, albumin, calcium lactobionate, and othersknown to those of ordinary skill in the art.

As used herein, the term “cryoprotectant” is intended to mean a compoundused to protect an active therapeutic agent from physical or chemicaldegradation during lyophilization. Such compounds include, by way ofexample and without limitation, dimethyl sulfoxide, glycerol, trehalose,propylene glycol, polyethylene glycol, and others known to those ofordinary skill in the art.

As used herein, the term “emulsifier” or “emulsifying agent” is intendedto mean a compound added to one or more of the phase components of anemulsion for the purpose of stabilizing the droplets of the internalphase within the external phase. Such compounds include, by way ofexample and without limitation, lecithin,polyoxylethylene-polyoxypropylene ethers, polyoxylethylene-sorbitanmonolaurate, polysorbates, sorbitan esters, stearyl alcohol, tyloxapol,tragacanth, xanthan gum, acacia, agar, alginic acid, sodium alginate,bentonite, carbomer, sodium carboxymethylcellulose, cholesterol,gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, octoxynol,oleyl alcohol, polyvinyl alcohol, povidone, propylene glycolmonostearate, sodium lauryl sulfate, and others known to those ofordinary skill in the art.

A solubility-enhancing agent can be added to the formulation of theinvention. A solubility-enhancing agent is a compound, or compounds,that enhance(s) the solubility of the active agent when in a liquidformulation. When such an agent is present, the ratio ofcyclodextrinlactive agent can be changed. Suitable solubility enhancingagents include one or more organic solvents, detergents, soaps,surfactant and other organic compounds typically used in parenteralformulations to enhance the solubility of a particular agent.

Suitable organic solvents include, for example, ethanol, glycerin,polyethylene glycols, propylene glycol, poloxomers, and others known tothose of ordinary skill in the art.

Formulations comprising the SAE-CD composition of the invention caninclude oils (e.g,, fixed oils, peanut oil, sesame oil, cottonseed oil,corn oil olive oil, and the like), fatty acids (e.g., oleic acid,stearic acid, isostearic acid, and the like), fatty acid esters (e.g.,ethyl oleate, isopropyl myristate, and the like), fatty acid glycerides,acetylated fatty acid glycerides, and combinations thereof. Formulationscomprising the SAE-CD composition of the invention can also includealcohols (e.g., ethanol, iso-propanol, hexadecyl alcohol, glycerol,propylene glycol, and the like), glycerol ketals (e.g.,2,2-dimethyl-1,3-dioxolane-4-methanol, and the like), ethers (e.g.,poly(ethylene glycol) 450, and the like), petroleum hydrocarbons (e.g.,mineral oil, petrolatum, and the like), water, surfactants, suspendingagents, emulsifying agents, and combinations thereof.

It should be understood, that compounds used in the art ofpharmaceutical formulations generally serve a variety of functions orpurposes. Thus, if a compound named herein is mentioned only once or isused to define more than one term herein, its purpose or function shouldnot be construed as being limited solely to that named purpose(s) orfunction(s).

Formulations comprising the SAE-CD composition of the invention can alsoinclude biological salt(s), sodium chloride, potassium chloride, andother electrolyte(s).

Since some active agents are subject to oxidative degradation, a liquidformulation according to the invention can be substantially oxygen-free.For example, the headspace of a container containing a liquidformulation can made oxygen-free, substantially oxygen-free, oroxygen-reduced by purging the headspace with an inert gas (e.g.,nitrogen, argon, carbon dioxide, and the like), or by bubbling an inertgas through a liquid formulation. For long-term storage, a liquidformulation containing an active agent subject to oxidative degradationcan be stored in an oxygen-free or oxygen-reduced environment. Removalof oxygen from the formulation will enhance preservation of theformulation against aerobic microbes; whereas, addition of oxygen to theformulation will enhance preservation against anaerobic microbes.

The phrase “pharmaceutically acceptable” is employed herein to refer tothose compounds, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of human beings and animals without excessive toxicity,irritation, allergic response, or other problem or complication,commensurate with a reasonable benefit/risk ratio.

As used herein, the term “patient” or “subject” are taken to mean warmblooded animals such as mammals, for example, cats, dogs, mice, guineapigs, horses, bovine cows, sheep, non-humans, and humans.

A formulation of the invention will comprise an active agent present inan effective amount. By the term “effective amount,” is meant the amountor quantity of active agent that is sufficient to elicit the required ordesired response, or in other words, the amount that is sufficient toelicit an appreciable biological response when administered to asubject.

The compositions of the present invention can be present in formulationsfor dosage forms such as a reconstitutable solid, tablet, capsule, pill,troche, patch, osmotic device, stick, suppository, implant, gum,effervescent composition, injectable ophthalmic or nasal solutions, orinhalable powders or solutions.

The invention also provides methods of preparing a liquid formulationcomprising one or more active agents and a SAE-CD composition, whereinthe SAE-CD composition comprises a sulfoalkyl ether cyclodextrin andless than 100 ppm of a phosphate. A first method comprises: forming afirst aqueous solution comprising a SAE-CD composition; forming a secondsolution or suspension comprising one or more active agents; and mixingthe first and second solutions to form a liquid formulation. A similarsecond method comprises adding one or more active agents directly to afirst solution without formation of the second solution. A third methodcomprises adding a SAE-CD composition directly to the asolution/suspension containing one or more active agents. A fourthmethod comprises adding a solution comprising one ore more active agentsto a powdered or particulate SAE-CD composition. A fifth methodcomprises adding one or more active agents directly to a powdered orparticulate SAE-CD composition, and adding the resulting mixture to asecond solution. A sixth method comprises creating a liquid formulationby any of the above methods and then isolating a solid material bylyophilization, spray-drying, aseptic spray drying, spray-freeze-drying,antisolvent precipitation, a process utilizing a supercritical. or nearsupercritical fluid, or another method known to those of ordinary skillin the art to make a powder for reconstitution.

Specific embodiments of the methods of preparing a liquid formulationinclude those wherein: 1) the method further comprises sterile filteringthe formulation using a filtration medium having a pore size of 0.1 μmor larger; 2) the liquid formulation is sterilized by irradiation orautoclaving; 3) the method further comprises isolating a solid from thesolution; 4) the solution is purged with nitrogen or argon or otherinert pharmaceutically acceptable gas such that a substantial portion ofthe oxygen dissolved in, and/or in surface contact with, the solution isremoved.

The invention also provides a reconstitutable solid pharmaceuticalcomposition comprising one ore more active agents, a SAE-CD compositionand optionally at least one other pharmaceutical excipient. When thiscomposition is reconstituted with an aqueous liquid to form a preservedliquid formulation, it can be administered by injection, infusion,topically, by inhalation or orally to a subject.

Some embodiments of the reconstitutable solid pharmaceutical compositionincludes those wherein: 1) the pharmaceutical composition comprises anadmixture of a SAE-CD composition and a solid comprising one or moreactive agents and optionally at least one solid pharmaceuticalexcipient, such that a major portion of the active agent is notcomplexed with a sulfoalkyl ether cyclodextrin prior to reconstitution;and/or 2) the composition comprises a solid mixture of a SAE-CDcomposition and one ore more active agents, wherein a major portion ofthe one or more active agents is complexed with the sulfoalkyl ethercyclodextrin prior to reconstitution.

A composition of the invention can be used in a pharmaceutical dosageform, pharmaceutical composition or other such combination of materials.These SAE-CD compositions are also useful as, but not limited to,analytical reagents, food and cosmetics adjuvants and/or additives, andas environmental clean-up agents.

In view of the above description and the examples below, one of ordinaryskill in the art will be able to practice the invention as claimedwithout undue experimentation. The foregoing will be better understoodwith reference to the following examples that detail certain proceduresfor the preparation of molecules, compositions and formulationsaccording to the present invention. All references made to theseexamples are for the purposes of illustration. The following examplesshould not be considered exhaustive, but merely illustrative of only afew of the many embodiments contemplated by the present invention.

EXAMPLES Example 1 Preparation of a SBE_(2.0)-β-CD Composition having aMonomodal Distribution Profile

A SBE₂-β-CD composition was prepared by the following procedure, inwhich an underivatized β-CD starting material present in an alkalineaqueous medium was derivatized with an SBE precursor to form a SBE-β-CDhaving an average degree of substitution of 2. The underivatized β-CDwas dissolved in 6.5 equivalents of 3.6 N NaOH aqueous solution, heatedto 50° C., and stirred until complete dissolution. The reactiontemperature was then increased to 70° C. to 75° C. Two (2) equivalentsof a sulfoalkylating agent (1,4-butanesultone) was then added over aperiod of 20 minutes. The total equivalents of sulfoalkylating agentadded was proportional to the degree of substitution of the SAE-CDproduct. The pH was monitored for 4 hours and never dropped below 12. Asecond portion of 2.7 equivalents of 3.5 M NaOH was charged and thereaction was allowed to continue at 70° C. for at least an addition 16hours. The reaction mixture was cooled and diluted with water (roughlyone half the total reaction volume). The solution was neutralized with 7M HCl to pH 6.5-7.5 and filtered through a 0.45 μm filter. The solutionwas purified by ultrafiltration using a 1000 MWCO membrane. Theultrafiltration end point was determined by capillary electrophoresiswherein the filtrate showed no or substantially no presence of4-hydroxybutane-1-sulfonic acid and/or disodium bis(4-sulfobutyl)ether,and by osmolarity, wherein the permeate samples had little to no ionpresent. The solution was further treated with activated carbon (0.12 gactivated carbon; grata of cyclodextrin), filtered through a 0.22 μmfilter and neutralized (pH 6.5-7). The resulting solution wasconcentrated to roughly a 50% solution by rotary evaporation at 50° C.to 60° C. under less than 30 mmHg vacuum. The solution was freeze-driedto yield the SBE_(2.0)-β-CD as a white solid.

Example 2

Preparation of a SBE_(3.1)-β-CD Composition having a MonomodalDistribution Profile

A SBE_(3.1)-β-CD composition was prepared by the following procedure, inwhich an underivatized β-CD starting material present in an alkalineaqueous medium was derivatized with an SBE precursor to form, aSBE-β-CD. The underivatized β-CD was dissolved in 6.5 equivalents of 3.6N NaOH aqueous solution, heated to 50° C., and stirred until it wascompletely dissolved. The reaction temperature was then increased to 70°C. to 75° C. Three (3) equivalents of 1,4-butanesultone was added over aperiod of 15 minutes. The amount of equivalents added was proportionalto the degree of substitution of the final product. The pH was monitoredduring the first 4 hours and never dropped below 12. A second portion of2.7 equivalents of 3.5 M NaOH was charged and the reaction was allowedto continue at 70° C. for at least an addition 16 hours. The reactionmixture was cooled and diluted with water (roughly one-half the totalreaction volume). The solution was neutralized with 7 M HCl to pH6.5-7.5 and filtered through a 0.45 μm filter. The solution was purifiedby ultrafiltration using a 1000 MWCO membrane. The ultrafiltration endpoint was determined by capillary electrophoresis wherein the filtrateshowed no or substantially no presence of 4-hydroxybutane-1-sulfonicacid and/or disodium bis(4-sulfobutyl)ether, and by osmolarity, whereinthe permeate samples had little to no ion present. The solution wasfurther treated with carbon (0.12 gram of carbon/gram of cyclodextrin),filtered through a 0.22 μm filter and neutralized (pH 6.5-7), Theresulting solution was concentrated to roughly a 50% solution by Rotaryevaporation at 50° C. to 60° C. under less than 30 mmHg vacuum. Thesolution was freeze-dried to yield a SBE_(3.1)-β-CD composition as awhite solid.

Example 3 Preparation of a SBE_(4.1)-β-CD Composition having a MonomodalDistribution Profile

A SBE_(4.1)-β-CD composition was prepared by the following procedure, inwhich an underivatized β-CD starting material present in an alkalineaqueous medium was derivatized with an SBE precursor to form a SBE-β-CD.The underivatized β-CD was dissolved in 6.5 equivalents of 3.6 N NaOHaqueous solution, heated to 50° C., and stirred until completedissolution. Once dissolution was complete the reaction temperature wasincreased to 70° C. to 75° C. Four (4) equivalents of 1,4-butanesultonewas added over a period of 20 minutes. The amount of equivalents addedwas proportional to the degree of substitution of the final product. ThepH was monitored during the first 4 hours and never dropped below 12. Asecond portion of 2.7 equivalents of 3.5 M NaOH was charged and thereaction was allowed to continue at 70° C. for at least an addition 16hours, The reaction mixture was cooled and diluted with water (roughlyone-half the total reaction volume). The solution was neutralized with 7M HCl to pH 6.5-7.5 and filtered through a 0.45 μm filter. The solutionwas purified by ultrafiltration using a 1000 MWCO membrane. Theultrafiltration end point was determined by capillary electrophoresiswherein the filtrate showed no or substantially no presence of4-hydroxybutane-1-sulfonic acid and/or disodium bis(4-sulfobutyl)ether,and by osmolarity, wherein the permeate samples had little to no ionpresent. The solution was further treated with carbon (0.12 gram ofearbonlgram of cyclodextrin), filtered through a 0.22 μm filter andneutralized (pH 6.5-7.5). The resulting solution was concentrated toroughly a 50% solution by rotary evaporation at 50° C. to 60° C. underless than 30 mmHg vacuum. The solution was freeze-dried to yield aSBE_(4.1)-β-CD as a white solid.

Example 4 Preparation of a SBE_(4.7)-β-CD Composition having a MonomodalDistribution Profile

A SBE_(4.7)-β-CD compositions was prepared by the following procedure,in which an underivatized β-CD starting material present in an alkalineaqueous medium was derivatized with an SBE precursor to form a SBE-β-CD.The underivatized β-CD was dissolved in 11 equivalents of 3.8 N NaOHaqueous solutions, heated and stirred until complete dissolution. Oncedissolution was complete the reaction temperature was increased to 70°C. to 80° C. Six (6) equivalents of 1,4-butanesultone was added over aperiod of 20 minutes. The pH was monitored during the first 4 hours andnever dropped below 13. The reaction was allowed to continue at 70° C.fbr at least an addition 16 hours. The reaction mixture was cooled anddiluted with water (roughly one half the total reaction volume). Thesolution was neutralized with 8.4 M HCl to pH 6.5-7.5 and filteredthrough a 0.45 μm filter. The solution was purified by ultrafiltrationusing a 10(M) MWCO membrane. The ultrafiltration end point wasdetermined by capillary electrophoresis wherein the filtrate showed noor substantially no presence of 4-hydroxybutane-1-sulfonic acid and/ordisodium bis(4-sulfobutyl)ether, and by osmolarity, wherein the permeatesamples had little to no ion present. The solution was filtered througha 0.22 μm filter and neutralized (pH 6.5-7.5). The resulting solutionwas concentrated to roughly a 50% solution by Rotary evaporation at 50°C. to 60° C. under less than 30 mmHg vacuum. The solution wasfreeze-dried to yield a SBE_(4.7)-β-CD solid white solid.

Example 5 Preparation of a SRE_(6.2)-β-CD Composition having a MonomodalDistribution Profile

A SBE_(6.2)-β-CD composition was prepared by the following procedure,air which an underivatized β-CD starting material present in an alkalineaqueous medium was derivatized with an SBE precursor to form a SBE-β-CD.The underivatized β-CD was dissolved in 11 equivalents of 3.7 N NaOHaqueous solution, heated to 50° C., and stirred until completedissolution. Once dissolution was complete the reaction temperature wasincreased to 70° C. to 75° C. Then, 6.8 equivalents of 1,4-butanesultonewas added over a period of 35 minutes. The pH was monitored during thefirst 4 hours and never dropped below 12.9. The reaction was allowed tocontinue at 70° C. for at least an addition 16 hours. The reactionmixture was cooled and diluted with water (roughly one half the totalreaction volume). The solution was neutralized with 7 M HCl to pH6.5-7.5 and filtered through a 0.45 μm filter. The solution was purifiedby ultrafiltration using a 1000 MWCO membrane. The ultrafiltration endpoint was determined by capillary electrophoresis wherein the filtrateshowed no or substantially no presence of 4-hydroxybutane-1-sulfonicacid and/or disodium bis(4-sulfobutyl)ether, and by osmolarity, whereinthe permeate samples had little to no ion present. The solution wasfurther treated with activated carbon (0.12 gram of activatedcarbon/gram of cyclodextrin), filtered through a 0.22 μm filter andneutralized (pH 6.5-7). The resulting solution was concentrated toroughly a 50% solution by Rotary evaporation at 50° C. to 60° C. underless than 30 mmHg vacuum. The solution was freeze-dried to yield aSBE_(6.2)-β-CD as a solid white solid.

Example 6 Preparation of a SBE_(6.8)-β-CD Composition having a MonomodalDistribution Profile

A SBE_(6.8)-β-CD composition was prepared by the following procedure, inwhich an underivatized β-CD starting material present in an alkalineaqueous medium was derivatized with an SBE precursor to form a SBE-β-CD,The underivatized β-CD was dissolved in 6.5 equivalents of 3.7 N NaOHaqueous solution, heated to 50° C., and stirred until completedissolution. Once dissolution was complete the reaction temperature wasincreased to 70° C. to 75° C. Then, 8.7 equivalents of 1,4-butanesultonewas added over a period of 40 minutes. The pH was monitored during thefirst 4 hours and never dropped below 8.6. A second portion of 4.4equivalents of 3.9 M NaOH was charged and the reaction was allowed tocontinue at 70° C. for at least an addition 16 hours. The reactionmixture was cooled and diluted with water (roughly one half the totalreaction volume). The solution was neutralized with 7 M HCl between 6.5to 7.5 and filtered through a 0.45 μm filter. The solution was purifiedby ultrafiltration using a 1000 MWCO membrane. The ultrafiltration endpoint was determined by capillary electrophoresis wherein the filtrateshowed no or substantially no presence of 4-hydroxybutane-1-sulfonicacid and/or disodium bis(4-sulfobutyl)ether, and by osmolarity, whereinthe permeate samples had little to no ion present. The solution wasfurther treated with carbon (0.12 gram of carbon/gram of cyclodextrin),filtered through a 0.22 μm filter and neutralized (pH 6.5-7). Theresulting solution was concentrated to roughly a 50% solution by rotaryevaporation at 50° C. to 60° C. under less than 30 mmHg vacuum. Thesolution was freeze-dried to provide SBE_(6.8)-β-CD as a white solid.

Example 7 Preparation of a SBE_(4.7)-β-CD Composition having a MonomodalDistribution Profile

A SBE_(4.2)-γ-CD composition was prepared by the following procedure, inwhich an underivatized γ-CD starting material present in an alkalineaqueous medium was derivatized with an SBE precursor to form a SBE-γ-CD.The underivatized γ-CD was dissolved in 6.5 equivalents of 3.9 N NaOHaqueous solution, heated to 70° C., and stirred until completedissolution. Once dissolution was complete the reaction temperature wasincreased to 70° C. to 75° C. Then, 4.2 equivalents of 1,4-butanesultonewas added over a period of 110 minutes. The pH was monitored during thefirst 4 hours and never dropped below 12.6. A second portion of 4.2equivalents of 6.3 M NaOH was charged and the reaction was allowed tocontinue at 70° C. for at least an addition 16 hours. The reactionmixture was cooled and diluted with water (roughly one third the totalreaction volume). The solution was further treated with carbon (0.07gram of carbon/gram of cyclodextrin), neutralized with 2.5 M HCl to pH6-6.5 and filtered through a 0.45 μm filter. The solution was purifiedby Ultrafiltration using a 650 MWCO membrane. The ultrafiltration endpoint was determined by capillary electrophoresis wherein the filtrateshowed no or substantially no presence of 4-hydroxybutane-1-sulfonicacid and/or disodium bis(4-sulfobutyl)ether, and by osmolarity, whereinthe permeate samples had little to no ion present. The solution wasfiltered through a 0.22 μm filter and neutralized (a pH 6-6.5). Theresulting solution was concentrated to roughly a 50% solution by rotaryevaporation at 50° C. to 60° C. under less than 30 mmHg vacuum. Thesolution was freeze-dried to yield a SBE_(4.2)-γ-CD as a white solid.

Example 8 Preparation of a SBE_(4.8)-γ-CD Composition having a MonomodalDistribution Profile

A SBE_(4.8)-γ-CD composition was prepared by the following procedure, inwhich an underivatized γ-CD starting material present in an alkalineaqueous medium was derivatized with an SBE precursor to form a SBE-γ-CD.The underivatized γ-CD was dissolved in 6.5 equivalents of 4 N NaOHaqueous solution, heated to 70° C. and stirred until completedissolution. Once dissolution was complete the reaction temperature wasincreased to 70° C. to 75° C., Then, 4.5 equivalents of1,4-butanesultone was added over a period of 103 minutes. The pH wasmonitored during the first 4 hours and never dropped below 12.4. Asecond portion of 4.3 equivalents of 6.3 M NaOH was charged and thereaction was allowed to continue at 70° C. for at least an addition 16hours. The reaction mixture was cooled and diluted with water (roughlyone third the total reaction volume). The solution was further treatedwith carbon (0.11 gram of carbon/gram of cyclodextrin), neutralized with2.5 M HCl to pH 6-6.5 and filtered through a 0.45 μm filter. Thesolution was purified by Ultrafiltration using a 650 MWCO membrane. TheUltrafiltration end point was determined by capillary electrophoresiswherein the filtrate showed no or substantially no presence of4-hydroxybutane-1-sulfonic acid and/or Disodiuin Bis(4-Sulfobutyl)Ether, and by Osmolarity, wherein the permeate samples hadlittle to no ion present. The solution was filtered through a 0.22 μmfilter and neutralized (pH 6-6.5). The resulting solution wasconcentrated to roughly a 50% solution by Rotary evaporation at 50° C.to 60° C. under less than 30 mmHg vacuum. The solution was freeze-driedto yield a SBE_(4.8)-γ-CD as a white solid.

Example 9 Preparation of a SBE_(5.8)-γ-CD Composition having a MonomodalDistribution Profile

A SBE_(5.8)-γ-CD composition was prepared by the following procedure, inwhich an underivatized γ-CD starting material present in an alkalineaqueous medium was derivatized with an SBE precursor to form a SBE-γ-CD.The γ-CD was dissolved in 6.5 equivalents of 4 N NaOH aqueous solution,heated to 70° C., and stirred until complete dissolution. Oncedissolution was complete the reaction temperature was increased to 70°C. to 75° C. Then, 5.8 equivalents of 1,4-butanesultone was added over aperiod of 77 minutes, The pH was monitored during the first 4 hours andnever dropped below 11.5. A second portion of 4 equivalents of 6.3 MNaOH was charged and the reaction was allowed to continue at 70° C. forat least an addition 16 hours. The reaction mixture was cooled anddiluted with water (roughly one third the total reaction volume). Thesolution was neutralized with 2.5 M HCl to pH 7-7.25, treated withactivated carbon (0.08 gram of activated carbon/gram of cyclodextrin),filtered through a 0.45 μm filter. The solution was purified byultrafiltration using a 500 MWCO membrane. The ultrafiltration end pointwas determined by capillary electrophoresis wherein the filtrate showedno or substantially no presence of 4-hydroxybutane-1-sulfonic acidand/or disodium bis(4-sulfobutyl)ether, and by Osmolarity, wherein thepermeate samples had little to no ion present. The solution was filteredthrough a 0.22 μm filter. The resulting solution was concentrated toroughly a 50% solution by Rotary evaporation at 50° C. to 60° C. underless than 30 mmHg vacuum. The solution was freeze-dried to yield aSBE_(5.8)-γ-CD as a white solid.

Example 10

Preparation of a SBE_(6.1)-γ-CD Composition having a MonomodalDistribution Profile

A SBE_(6.1)-γ-CD was prepared by the following procedure, whichunderivatized γ-CD starting material present in an alkaline aqueousmedium was derivatized with an SBE precursor to form a SBE-γ-CD. Theγ-CD was dissolved in 6.2 equivalents of 4 N NaOH aqueous solution atambient temperature and stirred until complete dissolution. Then, 6.5equivalents of 1,4-butanesultone was added. The pH was monitored duringthe first 4 hours and never dropped below 11. A second portion of 3.8equivalents of 6.3 M NaOH was charged and the reaction was allowed tocontinue at 70° C. for at least an addition 16 hours. The solution wasneutralized with 4.9 M HCl to pH 6-6.5, treated with activated carbon(0.08 gram of activated carbon/gram of cyclodextrin), filtered through a0.45 μm filter. The solution was purified by ultrafiltration using a 500MWCO membrane. The ultrafiltration end point was determined by capillaryelectrophoresis wherein the filtrate showed no or substantially nopresence of 4-hydroxybutane-1-sulfonic acid and/or disodiumbis(4-sulfobutyl)eEther, and by osmolarity, wherein the permeate sampleshad little to no ion present. The solution was neutralized (pH 6-6.5)and filtered through a 0.22 μm filter. The resulting solution wasconcentrated to roughly a 50% solution by rotary evaporation at 50° C.to 60° C. under less than 30 mmHg vacuum. The solution was freeze-driedto yield a SBE_(6.1)-γ-CD as a white solid.

Example 11

Preparation of SBE-β-CD having a Bimodal Distribution Profile and anAP-ADS of 4.6

An exemplary bimodal SBE-β-CD (AP-ADS 4.6) was made using the following,wherein the β-cyclodextrin was dissolved in 6.5 equivalents of 3.6 NNaOH. This solution was added over a period of 30 minutes to a stirredmixture of 6.5 equivalents of 1,4-butanesultone and 4.4 equivalents of4.2 N NaOH at 70° C. to 75° C. The reaction was allowed to continue at70° C. for at least an addition 16 hours. The reaction mixture wascooled and diluted with water (roughly one half the total reactionvolume). The solution was neutralized with 7.3 M HCl to pH 6.5-7.5 andfiltered through a 0.45 μm filter. The solution was purified byUltrafiltration using a 1000 MWCO membrane. The ultrafiltration endpoint was determined by capillary electrophoresis wherein the filtrateshowed no or substantially no presence of 4-hydroxybutane-1-sulfonicacid and/or disodium bis(4-sulfobutyl)ether, and by osmolarity, whereinthe permeate samples had little to no ion present. The solution wasfurther treated with carbon (0.12 gram of carbon/gram of cyclodextrin),filtered through a 0.22 μm filter and neutralized (pH 6-7). Theresulting solution was concentrated to roughly a 50% solution by rotaryevaporation at 50° C. to 60° C. under less than 30 mmHg vacuum. Thesolution was freeze-dried to yield an AP-ADS 4.62 bimodal SBE-β-CD whitesolid.

Example 12

Preparation of SBE- 3-CD having a Bimodal Distribution Profile and anAP-ADS of 6.6

An exemplary bimodal SBE-β-CD (AP-ADS 6.6) was made using the following,in which a β-cyclodextrin was dissolved in 12.6 equivalents of 3.7 NNaOH. This solution was added over a period of 30 minutes to 6.5equivalents of stirred 1,4-butanesultone at 70° C. to 75° C. Thereaction was allowed to continue at 70° C. for at least an addition 16hours. The reaction mixture was cooled and diluted with water (roughlyone half the total reaction volume). The solution was neutralized with7.3 M HCl to pH 6.5-7.5 and filtered through a 0.45 μm filter. Thesolution was purified by ultrafiltration using a 1000 MWCO membrane. Theultrafiltration end point was determined by capillary electrophoresiswherein the filtrate showed no or substantially no presence of4-hydroxybutane-1-sulfonic acid and/or disodium bis(4-sulfobutyl)ether,and by osmolarity, wherein the permeate samples had little to no ionpresent. The solution was further treated with carbon (0.12 gram ofcarbon/gram of cyclodextrin), filtered through a 0.22 μm filter andneutralized (pH 6-7). The resulting solution was concentrated to roughlya 50% solution by Rotary evaporation at 50° C. to 60° C. under less than30 mmHg vacuum. The solution was freeze-dried to yield a AP-ADS 6.6bimodal SBE-β-CD white solid.

Example 13

Preparation of SBE-β-CD having a Bimodal Distribution Profile and anAP-ADS of 6.9

An exemplary bimodal SBE-β-CD (AP-ADS 6.9) was made using the following,in which a β-cyclodextrin was dissolved in 10.9 equivalents of 3.8 NNaOH. This solution was added over a period of 65 minutes to 6.5equivalents of stirred 1,4-butanesultone at 70° C. to 75° C. Thereaction was allowed to continue at 70° C. for at least an addition 16hours. The reaction mixture was cooled and treated with carbon (0.12gram of carbon/gram of cyclodextrin). The solution was filtered, dilutedwith water (roughly one twentieth the total reaction volume). Thesolution was further neutralized with 8.25 M HCl to pH 6-7 and filteredthrough a 0.45 μm filter. The solution was purified by ultrafiltrationusing a 650 MWCO membrane. The ultrafiltration end point was determinedby capillary electrophoresis wherein the filtrate showed no orsubstantially no presence of 4-Hydroxybutane-1-sulfonic acid and/ordisodium bis(4-sulfobutyl)ether, and by osmolarity, wherein the permeatesamples had little to no ion present. The resulting solution wasconcentrated to roughly a 50% solution by Rotary evaporation at 50° C.to 60° C. under less than 30 mmHg vacuum. The solution was freeze-driedto yield a AP-ADS 6.9 bimodal SBE-β-CD white solid.

Example 14 Preparation of SBE-γ-CD having a Bimodal Distribution Profileand an AP-ADS of 3.8

An exemplary bimodal SBE-γ-CD (AP-ADS 3.8 was made using the following,in which a γ-cyclodextrin was dissolved in 12.5 equivalents of 3.7 NNaOH. This solution was added over a period of 30 minutes to 4.25equivalents of stirred 1,4-butanesultone at 65° C. to 72° C. Thereaction was allowed to continue at 70° C. for at least an addition 16hours. The reaction mixture was cooled and neutralized with 8.9 M HCl topH 6.5-7.5. The solution was diluted with water (roughly one half thetotal reaction volume). The resulting solution was filtered through a0.45 μm filter. The solution was purified by Ultrafiltration using a1000 MWCO membrane. The Ultrafiltration end point was determined bycapillary electrophoresis wherein the filtrate showed no orsubstantially no presence of 4-hydroxybutane-1-sulfonic acid and/ordisodium bis(4-sulfobutyl)ether, and by osmolarity, wherein the permeatesamples had little to no ion present. The solution was further treatedwith carbon (0.12 gram of carbon/gram of cyclodextrin), filtered througha 0.22 μm filter and neutralized (pH 6-7). The resulting solution wasconcentrated to roughly a 50% solution by Rotary evaporation at 50° C.to 60° C. under less than 30 mmHg vacuum. The solution was freeze-driedto yield a AP-ADS 3.8 bimodal SBE-γ-CD white solid.

Example 15 Preparation of SBE-γ-CD having a Bimodal Distribution Profileand an AP-ADS of 6.5

An exemplary bimodal SBE-γ-CD (AP-ADS 6.5) was made using the following,in which a γ-cyclodextrin was dissolved in 12.5 equivalents of 3.7 NNaOH. This solution was added over a period of 35 minutes to 6.5equivalents of stirred 1,4-butanesultone at 67° C. to 74° C. Thereaction was allowed to continue at 70° C. for at least an addition 16hours. The reaction mixture was cooled and neutralized with 8.5 M HCl topH 6.5-7.5. The solution was diluted with water (roughly one half thetotal reaction volume). The resulting solution was filtered through a0.45 μm filter. The solution was purified by Ultrafiltration using a1000 MWCO membrane. The Ultrafiltration end point was determined bycapillary electrophoresis wherein the filtrate showed no orsubstantially no presence of 4-hydroxybutane-1-sulfonic acid and/ordisodium bis(4-sulfobutyl)ether, and by osmolarity, wherein the permeatesamples had little to no ion present. The solution was further treatedwith carbon (0.12 gram of carbon/gram of cyclodextrin), filtered througha 0.22 μm fitter and neutralized (pH 6-7). The resulting solution wasconcentrated to roughly a 50% solution by Rotary evaporation at 50° C.to 60° C. under less than 30 mmHg vacuum. The solution was freeze-driedto yield a AP-ADS 6.5 bimodal SBE-γ-CD white solid.

Example 16

Preparation of SBE-γ-CD having a Bimodal Distribution Profile and anAP-ADS of 6.9

An exemplary bimodal SBE-γ-CD (AP-ADS 6.9) was made using the following,in which a γ-cyclodextrin was dissolved in 12.5 equivalents of 3.7 NNaOH. This solution was added over a period of 38 minutes to 10equivalents of stirred 1,4-butanesultone at 66° C. to 73° C. Thereaction was allowed to continue at 70° C. for at least an addition 16hours. The reaction mixture was cooled and neutralized with 8.5 M HCl topH 6.5-7.5. The solution was diluted with water (roughly one half thetotal reaction volume). The resulting solution was filtered through a0.45 μm filter. The solution was purified by ultrafiltration using a1000 MWCO membrane. The ultrafiltration end point was determined bycapillary electrophoresis wherein the filtrate showed no orsubstantially no presence of 4-hydroxybutane-1-sulfonic acid and/ordisodium bis(4-sulfobutyl)ether, and by osmolarity, wherein the permeatesamples had little to no ion present. The solution was further treatedwith carbon (0.12 gram of carbon/gram of cyclodextrin), filtered througha 0.22 μm filter and neutralized (pH 6-7). The resulting solution wasconcentrated to roughly a 50% solution by Rotary evaporation at 50° C.to 60° C. under less than 30 mmHg vacuum. The solution was freeze-driedto yield a AP-ADS 6.9 bimodal SBE-γ-CD white solid.

Example 17 Determination of Active Agent Solubility

Comparative evaluation of the solubilization effect of varioussulfoalkyl ether cyclodextrin compositions on pharmaceutical activeagents was determined as follows. A 0.04 M stock solutions of eachselected cyclodextrin was prepared with purified water. Clarity ofsolutions was determined by visual inspection or instrumentally. A clearsolution is at least clear by visual inspection with the unaided eye.Each pharmaceutical active agent, tested in duplicate, was combined with2 mL or 4 mL of a SAE-CD aqueous solution.

Pharmaceutical active agents were weighed in amounts in excess of theiranticipated solubility, and placed in TEFLON®-lined screw-capped vials.The active agents were present in amounts of at least 3 mg/mL. Each vialwas then filled with the appropriate amount of cyclodextrin solution(either 2 mL or 4 mL). The vials were vortexed and sonicated to aid inwetting the solids with the fluid. The vials were then placed on a labquake or a roller mixer for equilibration. The vials were visuallyinspected periodically to assure that the solids were adequately beingwetted and in contact with the fluid. The fluid within the vials wasthen sampled periodically to determine the concentration of thepharmaceutical active agent present in solution. Samples were typicallymeasured at 24 hr intervals.

Sampling of the vials to detei mine active agent solubility wasperformed by decanting 1 mL of solution from the vial followed byoptional centrifuging. The removed supernatant was then filtered using a0.22 μm syringe filter, and diluted with the mobile phase to anappropriate concentration within the standard curve. The samples werethen analyzed by HPLC to determine concentration of the solubilized drugderivatives.

Example 18 Determination of Moisture Content

The following procedure was used to evaluate the moisture content thecyclodextrin derivatives. Determinations were performed in duplicate on250 mg of each using a Brinkman Karl-Fischer Coulometer (BrinkmanInstruments Co., IL). A known weight of solid cyclodextrin was added tothe Karl-Fischer Coulometer and the total amount of water in the sampleis measured. The total amount of water present is then converted to apercentage of the solid to give the percent moisture content of thesample.

Example 19 Analysis by Capillary Electrophoresis

The following procedure was used to analyze the SAE-CD derivativecompositions by capillary electrophoresis. A Beckman PACE 2210 capillaryelectrophoresis system coupled with a UV absorbance detector (Beckmaninstruments, Inc., Fullereton, Calif.) was used to analyze solutions ofSBE-β-CD and SBE-γ-CD derivatives. The separations were performed at 25°C. using a fused silica capillary (having a 50 μm inner diameter, atotal length of 57 cm, and an effective length of 50 cm) with a pHadjusted running buffer of 30 mM benzoic acid and 100 mM TRIS(tris-hydroxymethyl-aminomethanol).

The capillary was treated with the following wash sequence before eachinjection with water, 0.01 N NaOH, and running buffer. The detector wasset at 214 nm. The voltage was 30 kV. Samples were introduced bypressure injections: 20 seconds at 0.5 psi.

Example 20

An α-CD derivative composition having a monomodal distribution profilecan be prepared according to any of Examples 1-10 or any of theliterature methods cited herein, except that α-CD would be used in placeof the β-CD or γ-CD. An exemplary SBE-α-CD is made using the following,wherein an a-cyclodextrin in an alkaline aqueous medium is derivatizedwith an SBE precursor to form the SBE-α-CD. The α-CD is dissolved inNaOH aqueous solution, heated to 70° C., and stirred until completedissolution. Once dissolution is complete the reaction temperature isincreased to 70° C. to 75° C. Then, 1,4-butanesultone was added over aperiod of at least 30 minutes. The pH is monitored during the first 4hours and the reaction is allowed to continue at 70° C. for at least anaddition 16 hours. The reaction mixture is cooled and diluted with water(roughly one third the total reaction volume). The solution is furthertreated with carbon (0.07 gram of carbon/gram of cyclodextrin),neutralized with HCl to pH 6-6.5 and filtered through a 0.45 μm filter.The solution is purified by ultrafiltration using a 650 MWCO membrane.The ultrafiltration end point is determined by capillary electrophoresiswherein the filtrate showed no or substantially no presence of4-hydroxybutane-1 -sulfonic acid and/or disodium bis(4-sulfobutyl)ether,and by osmolarity, wherein the permeate samples had little to no ionpresent. The solution is filtered through a 0.22 μm filter andneutralized (pH 6-6.5). The resulting solution is concentrated toroughly a 50% solution by rotary evaporation at 50° C. to 60° C. underless than 30 mmHg vacuum. The solution is freeze-dried to yield aSBE-α-CD white solid.

Example 21 Preparation of Combination Composition Having a BimodalDistribution Profile

A previously prepared batch of cyclodextrin derivative composition,having a monomodal or bimodal distribution profile, is placed in aqueousalkaline liquid medium. A substituent precursor is placed in anoptionally alkaline liquid medium in a vessel. The alkaline mediumcontaining cyclodextrin derivative composition is added to the mediumcontaining the substituent precursor in a drop-wise, portion-wise,semi-continuous, or continuous manner for a period of time sufficient,at a temperature sufficient, and a pH sufficient to form a reactionmilieu comprising a combination composition having a bimodal ortrimodal, respectively, distribution profile. For example, the dissolvedbatch of derivatized composition is added over a period of at least 30minutes to the substituent precursor. The pH is monitored during thefirst 4 hours and the reaction is allowed to continue at 70° C. for atleast an addition 16 hours. The reaction mixture is cooled and dilutedwith water (roughly one third the total reaction volume). Thecombination composition is optionally further purified to removeunwanted components and/or add wanted components. For example, thesolution is further treated with carbon (0.07 gram of carbon/gram ofcyclodextrin), neutralized with HCl to pH 6.5-7.5 and filtered through a0.45 μm filter. The solution is purified by ultrafiltration using a 650MWCO membrane. The ultrafiltration end point is determined by capillaryelectrophoresis wherein the filtrate showed no or substantially nopresence of 4-hydroxybutane-1-sulfonic acid and/or disodiumbis(4-sulfobutyl)ether, and by osmolarity, wherein the permeate sampleshad little to no ion present. The solution is filtered through a 0.22 μmfilter and neutralized (pH 6-6.5). The resulting solution isconcentrated to roughly a 50% solution by Rotary evaporation at 50° C.to 60° C. under less than 30 mmHg vacuum. The solution is freeze-driedto yield a SBE-α-CD white solid.

Example 22 SBE_(6.6)-β-CD Synthesis

A SBE_(6.6)-β-CD composition was synthesized according to the followingprocedure, in which a β-cyclodextrin in an alkaline aqueous medium wasderivatized with an SBE precursor to form the SBE_(6.6)-β-CD. An aqueoussolution of sodium hydroxide was prepared by charging 61.8 kg of sodiumhydroxide to 433 kg of water for a 12.5% wiw solution. The reactorcontents were heated to 40° C. to 50° C. before beginning the additionof 270 kg of β-CD over 30 to 60 minutes. The reaction temperature wasadjusted to 65° C. to 95° C. before the addition of 259 kg of 1,4-butanesultone over 30 to 60 minutes. Over the next 6 hours the pH of thesolution was maintained above 9 using an aqueous solution of sodiumhydroxide. Following the reaction an additional 13.5 kg of sodiumhydroxide as a 20% solution were charged to the reaction. The contentswere maintained at 70° C. to 80° C. until the residual level of1,4-butane sultone were sufficiently low. The contents were cooled toless than 30° C. and the reaction solution was adjusted to pH 6.5-7.5with aqueous solution of hydrochloric acid. This process yielded 350 to450 kg of SAE-CD.

Example 23 SBE_(6.6)-β-CD Diafiltration and Ultrafiltration

The SBE_(6.6)-β-CD of Example 22 was purified by the followingprocedure. The reaction solution was diluted with 800 kg of water. Thesolution was transferred and further diluted with 500 kg of water.Diafiltration was initiated using a Millipore Helicon AutomatedUltrafiltration System using 1000 MWCO spiral wound regeneratedcellulose membranes having at least 750 ft² of membrane area andmaintaining a constant solution volume (±1%) until a sample of thereturnate has 25 ppm or less of sodium chloride. The solution wasconcentrated by ultrafiltration until an appropriate solution mass wasbeen achieved.

Example 24 SBE_(6.6)-β-CD Carbon Processing of the Present Invention

Following the diafiltration and ultrafiltration in Example 23, theSBE_(6.6)-β-CD was carbon purified by the following procedure. A columnwas charged with 32 kg (about 11-12% wt. (11.8-12% wt.) of the startingamount of β-cyclodextrin) of SHIRASAGI® DC32 granular activated carbonand washed thoroughly with water until the wash samples have a constantconductivity. The ratio of SBE_(6.6)-β-CD to activated carbon was about8.4:1 to 8.5:1 (about 8.44:1). Once washed, the reaction solution waspassed (recycled) through the carbon for at least 2 hours to complete afirst treatment cycle.

A second column was charged with 32 kg (about 11-12% wt. of the startingamount of β-cyclodextrin) of SHIRASAGI®) DC32 granular activated carbonand washed thoroughly with water until the wash samples have a constantconductivity. Once washed, the reaction solution was passed through thecarbon for at least 2 hours to complete a second treatment cycle.

Example 25 SBE_(6.6)-β-CD Concentration and Isolation

The carbon-treated SBE_(6.6)-β-CD solutions prepared in Example 24 wereconcentrated and isolated using the following procedure: aSBE_(6.6)-β-CD solution was filtered through 0.65 μm and 0.22 μm filtersand then concentrated at a reduced pressure of −0.6 bar to −0.7 bar at atemperature of 65° C. to 72° C., with agitation at 70 rpm to 100 rpm,until a solution having a SBE_(6.6)-β-CD concentration of 50% w/w wasachieved. The concentrated solution was cooled to below 60° C., and thenfiltered through 0.65 μm and 0.22 μm filters. The filtered solution wasthen spray dried using a fluidized spray dryer (“FSD”) system at aninlet temperature of 170° C., an initial pressure of 20 bar, andchambers 1-3 having set points of 125° C., 105° C., and 100° C.,respectively.

Example 26 Determination of Cyclodextrin Substitution Pattern by ¹H-NMR,¹³C-NMR, COSY-NMR and HMQC on a Bruker AVANCE® 400 or 500 Instrument inD₂O Solutions

Determination of the substitution pattern is conducted according to themethod of Example 6 of WO 2005/042584, the relevant disclosures of whichare hereby incorporated by reference.

Example 27 SBE_(6.6)-β-CD Comparative Carbon Processing

An exemplary SBE_(6.6)-β-CD was carbon purified by the followingprocedure: a column was charged with 32 kg (about 11-12% wt. (11.8-12%wt.) of the starting amount of β-cyclodextrin in Example 22) ofSHIRASAGI® DC32 granular activated carbon and washed thoroughly withwater until the wash samples have a constant conductivity. Once washedthe reaction solution was passed through the carbon for at least 2hours.

Example 28 SBE_(6.6)-β-CD Impurity Analysis I

SBE_(6.6)-β-CD samples treated either once or twice with activatedcarbon according to Examples 27 and 24, respectively, concentrated andisolated by the process described in Example 25, and were then analyzedby UV/vis spectrophotometry. The analysis was performed by dissolving anappropriate amount of SBE_(6.6)-β-CD in water (e.g., 0.1 g to 6 g ofSBE_(6.6)-β-CD, corrected for water content, dissolved in 10 mL ofwater) to provide solutions containing from 1% to 60% w/w of thederivatized eyetodextrin.

The carbon-treated cyclodextrin solutions were analyzed on a PerkinElmer Lambda 35 UV/Vis spectrophotometer, scanning from 190 nm to 400 nmat a speed of 240 nm/min and a slit width of 1.0 nm. The samples wereblanked against water before analysis. The UV/vis absorption spectra ofvarious concentrations of SBE_(6.6)-β-CD solutions after one and twoactivated carbon treatments is provided graphically in FIGS. 1 and 2,respectively, which provide a graphic representation of theSRE_(6.6)-β-CD lots after one or two carbon treatments analyzed by theUV method. Referring to FIG. 1, the data shows that a higherconcentration of impurities having an absorption in the UV/visibleregion of the spectrum is present when an SBE_(6.6)-β-CD solution istreated only once with activated carbon. Retelling to FIG. 2, the datashow that a second carbon treatment reduces the level of UV/visabsorbing impurities at least five fold or more.

Example 29 SBE_(6.6)-β-CD Impurity Analysis II Colorimeter AnalysisMethod

The SBE_(6.6)-β-CD samples were analyzed by Hunter Labs Colorimeterusing the Following procedure: 50% w/w solutions were prepared bydissolving 15 grams of SBE_(6.6)-β-CD (corrected for water content) in30 mL of water. The prepared solutions were analyzed on a Hunter LabULTRASCAN® colorimeter using Hunter Labs universal software, version4.10. The instrument was standardized against USP matching colorsolutions, cupric sulfate CS, ferric chloride CS, and cobalt chlorideCS. Samples were added to a 1 cm Hunter cuvette. The greater the DEvalue the more visible color a solution. Therefore SBE_(6.6)-β-CD LotNo. 17CX01.HQ00025 contained the most visible color while SBE_(6.6)-β-CDLot No. 17CX01.HQ00029 contained the least visible color. SBE_(6.6)-β-CDLot No. 17CX01.HQ00041 was slightly more than Lot No. 17CX01.HQ00029,but contained about five-fold fewer impurities having an absorption inthe ultraviolet region of the spectrum. The table below includes thedata obtained from analysis of SAE-CD lots with one or two carbontreatments analyzed by the Hunter colorimeter.

Sample Description L a DE 50% w/w 17CX01.HQ00041 96.85 −0.29 0.24 50%w/w 17CX01.HQ00029 96.88 −0.32 0.16 50% w/w 17CX01.HQ00025 96.24 −0.391.98 L = lightness; 100 for perfect white and 0 for black; a = measuresredness when positive, grey when zero, and greeness when negative; b =measures yellowness when positive, grey when zero, and blueness whennegative; DE = Total Differences √(ΔL² + Δa² + Δb²) from the Standard

Example 30 SBE₆₆-β-CD Impurity Analysis III

An exemplary SBE_(6.6)-β-CD sample was analyzed by analyzed by UV/Visspectrophotometry using the following procedure: a 50% w/wSBE_(6.6)-β-CD solution was prepared by dissolving 54.1 grams ofSBE_(6.6)-β-CD, corrected for water content, in a caustic solution of12.5 grams of sodium hydroxide in 100 mL of water. The initial solutionwas analyzed on a PERKIIN ELMER Lambda 35 UV/Vis spectrophotometer,scanning from 190 nm to 400 nm at a speed of 240 nm/min and a slit widthof 1.0 nm. The sample was blanked against water before analysis. Thesolution was placed in a 60° C. oven for up to 168 hours. Solutionsamples were analyzed at 24 hours, 72 hours, 96 hours and 168 hours.

FIG. 3 provides a graphical representation of the results from thethermal and caustic stress on the SBE_(6.6)-β-CD compositions. Referringto FIG. 3, the data shows that within 24 hours, a significant absorptionat a wavelength of 245 nm to 270 nm has formed, and that this absorptionincreases with the duration of thermal and caustic exposure. By 168hours (7 days), the absorption maximum at a wavelength of 245 nm to 270nm has increased to an equal magnitude with the absorption having amaximum at about 230 nm. Also of note is that the absorption at awavelength of 320 nm to 350 nm also increases with time of exposure. Thedata shows that a drug-degrading impurity having an absorption at awavelength of 245 nm to 270 nm, as well as a color forming agent havingan absorption at a wavelength of 320 nm to 350 nm, increase inconcentration over time under exposure to heat and/or causticconditions.

Example 31 SBE_(6.6)-β-CD Formulation Stability

Comparative evaluation of the stability of various lots ofSBE_(6.6)-β-CD that underwent a single or a double treatment withactivated carbon (according to Examples 27 and 24, respectively) wereformulated with a glucocorticosteroid (budesonide) and an excipient(water), and were examined by HPLC. The general procedure is providedbelow.

SBE_(6.6)-β-CD solutions (7.5% w/w, formulated with SBE_(6.6)-β-CD LotNos. 17CX01.HQ00025, 17CX01.HQ00029 and 17CX01.HQ00041), were preparedby dissolving about 7.5 grams of SBE_(6.6)-β-CD (corrected for watercontent) in 100 mL of water. A glucocorticosteroid was weighed inamounts in excess of the anticipated solubilities directly intoTEFLON®-lined screw-capped containers. Approximately 275 μg/mL of theglucocorticoid steroid was vigorously stirred for 2 hours in an amberglass container. At the end of the agitation time, theglucocorticosteroid solution was filtered using a 0.24 μm syringefilter.

Control solution samples were removed before autoclaving. Aliquots ofthe solutions were autoclaved for four 20 minute cycles at 121° C. Thesamples were then analyzed by HPLC to determine assay content and thelevel of impurities formed during the heating cycles. Solution samplesof SBE_(6.6)-β-CD were prepared and analyzed on a PERKIN ELMER Lambda 35UV/Vis spectrophotometer, scanning from 190 nm to 400 nm at a speed of240 nm/min and a slit width of 1.0 nm to determine the UV content.

Glucocorticoid Steroid HPLC Conditions:

Instrument Shimadzu PROMINENCE ® Column: GL Science INERTSIL ® S-3 (4.6mm × 250 mm × 5 μm) Mobile Phase A: 64% phosphate buffer/33.5%acetonitrile/2.5% methanol Mobile Phase B: 47.5% phosphate buffer/50%acetonitrile/2.5% methanol Wavelength: 240 nm Flow Rate: 1.5 mL/minColumn Temp: 40° C. Injection Volume: 50 μL

SBE_(6.6)-β-CD Solution UV Analysis

UV Analysis (MaxAbs @ λ = SBE_(6.6)-β-CD Lot No. 245-270 nm 50% w/w17CX01.HQ00041 0.130 50% w/w 17CX01.HQ00029 0.339 50% w/w 17CX01.HQ000250.652

Assay and Impurity Analysis of Heat-StressedSBE_(6.6)-β-CD/Glucocortieosteroid

Impurities Assay A B¹ R-GS¹ S-GS³ GS Total Δ Lot No. Area % Area % Area% Area % Area % % Glucocorticosteroid (“GS”) 0.001 0.127 51.888 47.49799.385 0 Std. 17CX01.HQ00025^(a,) * 0.010 0.132 51.799 47.483 99.2820.103 17CX01.HQ00025^(b) 0.096 0.134 32.879 36.213 69.092 30.29317CX01.HQ00029^(a,) * 0.003 0.140 51.784 47.498 99.282 0.10317CX01.HQ00029^(b) 0.207 0.164 50.656 46.86 97.516 1.86917CX01.HQ00041^(a,) * 0.001 0.130 51.778 47.526 99.304 0.08117CX01.HQ00041^(b) 0.058 0.139 38.138 39.791 77.929 21.456 ¹Impurity Bwas identified as the S-11-keto-derivative of the glucocorticosteroid.²“R-GS” refers to the R-enantiomer of the glucocorticosteroid. ³“S-GS”refers to the S-enantiomer of the glucocorticosteroid. *Lot Nos.17CX01.HQ00025 and 17CX01.HQ00041 underwent a single treatment withactivated carbon (see Example 27), white Lot No. 17CX01.HQ00029underwent a double activated carbon treatment (see Example 24). ^(a)Asmeasured initially (t = 0). ^(b)Treatment for 80 minutes at 121° C.

The results of the study show that SBE_(6.6)-β-CD compositions thatcontain a low amount of UV-active drug-degrading impurities provide morestable API formulations and lower API degradation. The addition of ahigher SBE_(6.6)-β-CD solution color does not dictate a higher level ofglucocorticosteroid impurities. Furthermore, based on the stability ofthe glucocorticosteroid, SBE_(6.6)-β-CD Lot No. 17CX01.HQ00041 wassignificantly better at stabilizing the isomers of theglucocorticosteroid than SBE_(6.6)-β-CD Lot No. 17CX01.HQ00025.

Example 32 SBE_(6.6)-β-CD Formulation Stability with Triazole AntifungalAPI

SBE_(6.6)-β-CD compositions that underwent single- or double-treatmentwith activated carbon (according to Examples 27 and 24, respectively)were formulated with a triazole antifungal API (posaconazole, which waspurchased from Schering-Plough as an aqueous oral suspension, NOXAFIL®)and the stability of the API formulation was determined by Huntercolorimetric and HPLC analysis. The formulation procedure is providedbelow.

Aqueous solution samples of a triazole antifungal API (5 mg/mL) and aSBE_(6.6)-β-CD composition (100 pH 3) were prepared using SBE_(6.6)-β-CDLot Nos. 17CX01.HQ00044, 17CX01.HQ00037, 17CX01.HQ00035, 17CX01.H900033and 17CX01.HQ00029. All solution samples were filtered through 0.22 μmPVDF filter, and separated into vials. The UV/Vis absorption of aportion of the initial solutions was measured using a 1 cm Huntercuvette on a PERKIN ELMER Lambda 35 UV/Vis spectrophotometer, scanningfrom 190 nm to 400 nm at a speed of 240 nm/min and a slit width of 1.0nm, and analyzed on a Hunter Labs ULTRASCAN® colorimeter using HunterLabs universal software, version 4.10. The samples were blanked againstwater before measurement. The remaining portions of samples were thenplaced into a 60° C. oven for 7 days and then reanalyzed for colorchanges using the same procedure. The data is shown in the followingtables.

SBE_(6.6)-β-CD Initial Solutions: UV/Vis Analysis

30% SBE_(6.6)-β-CD UV analysis Solutions Carbon (Max Abs @ λ = Lot No.Processing Condition 245-270 nm) 17CX01.HQ00044 2 Granular carbontreatments 0.05 (SHIRASAGI ® DC-32) 17CX01.HQ00037 2 Granular carbontreatments 0.11 (SHIRASAGI ® DC-32) 17CX01.HQ00035 2 Granular carbontreatments 0.16 (SHIRASAGI ® DC-32) 17CX01.Q00033 1 Granular carbontreatments 0.25 (SHIRASAGI ® DC-32) 17CX01.HQ00029 1 Granular carbontreatments 0.32 (SHIRASAGI ® DC-32)

SBE₆₆-β-CD Solution Color Analysis

t = 7 days SBE_(6.6)-β-CD t = 0 @ 60° C. (100 mM) Carbon ProcessingCond. (DE) (DE) 1.7CX01.HQ00044 2 Granular carbon treatments 0.08 0.01(SHIRASAGI ® DC-32) 17CX01.HQ00037 2 Granular carbon treatments 0.120.15 (SHIRASAGI ® DC-32) 17CX01.HQ00035 2 Granular carbon treatments0.09 0.18 (SHIRASAGI ® DC-32) 17CX01.HQ00033 1 Granular carbontreatments 0.2 0.41 (SHIRASAGI ® DC-32) 17CX01.HQ00029 1 Granular carbontreatments 0.12 0.38 (SHIRASAGI ® DC-32) L = lightness; 100 for perfectwhite and 0 for black; a = measures redness when positive, grey whenzero, and greeness when negative; b = measures yellowness when positive,grey when zero, and blueness when negative; DE = Total Differences√(ΔL² + Δa² + Δb²) from the Standard

Triazole API/SBE_(6.6)-β-CD Solution Color Analysis

UV/Vis Analysis (DE) t = 0 t = 7 days @ Formulation (DE) 60° C. (DE)17CX01.HQ00044 0.46 4.37 17CX01.HQ00037 0.2 3.76 17CX01.HQ00035 0.244.43 17CX01.HQ00033 0.45 5 17CX01.HQ00029 0.36 6.26 L = lightness; 100for perfect white and 0 for black; a = measures redness when positive,grey when zero, and greeness when negative; b = measures yellowness whenpositive, grey when zero, and blueness when negative; DE = TotalDifferences √(ΔL² + Δa² + Δb²) from the Standard.

Triazole API/SBE_(6.6)-β-CD Triazole API Assay Analysis

Triazole API Assay Δ Assay SBE_(6.6)-β-CD t = 7 days (t = 0 →   Lot No.t = 0 @ 60° C. t = 7 days) 17CX01.HQ00044 99.94% 99.80 0.1417CX01.HQ00037 99.98% 99.61 0.36 17CX01.HQ00035 99.97% 99.60 0.3717CX01.HQ00033 99.96% 99.60 0.36 17CX01.HQ00029 99.95% 99.57 0.38

The LTV analysis demonstrated that the UV-active impurities present inthe initial SBE_(6.6)-β-CD composition are much lower when a thecyclodextrin composition is treated twice with activated carbon. TheHunter color analysis of the SBE_(6.6)-β-CD composition alone, as wellas the triazole API/SBE_(6.6)-β-CD formulation samples indicated lowerDE values for those SBE_(6.6)-β-CD lots that were processed using adouble activated carbon treatment. There was little difference betweenthe triazole API assay content before and after the 7 day-60° C. stresstest. Thus, the lower impurity levels in the SBE_(6.6)-β-CD compositionthat was treated twice with activated carbon results in less a reducedlevel of triazole API degradation, as well as reduced formation ofcolor-forming agents.

Example 33 SBE_(6.6)-β-CD DS Subjected to Heat then Carbon Treatment

The effect of heating a derivatized cyclodextrin composition of thepresent invention was studied as follows. The SBE_(6.6)-β-CD compositionprepared according to Example 22 was dissolved in aqueous solution andanalyzed using UV/vis spectrophotometry. Specifically, a 30% w/wβ-cyclodextrin solution was prepared by dissolving 70 grams ofSBE_(6.6)-β-CD Lot No. 17CX01.HQ00044 (corrected for water content) in230 mL of water. This initial solution was analyzed on a PERKIN ELMERLambda 35 UV/Vis spectrophotometer, scanning from 190 nm to 400 nm at aspeed of 240 nm/min and a slit width of 1.0 nm. The sample was blankedagainst water before analysis. The solution was heated with agitation to70 for 48 hours. The solution was cooled to ambient temperature anddivided. To each of the divided solutions, pre-washed SHIRASAGI® DC32granular activated carbon was added. The SBE_(6.6)-β-CD solutions werestirred for 3 hours, and then the activated carbon was filtered using a0.22 μm PVDF filter. The solutions were analyzed using a PERKIN ELMERLambda 35 UV/Vis spectrophotometer, scanning from 190 nm to 400 nm at aspeed of 240 nm/min and a slit width of 1.0 nm. The samples were blankedagainst water before analysis.

The data is depicted graphically in FIG. 4. Referring to FIG. 4, theUV/vis absorption of the solution prior to heat treatment (++++),immediately after 48 hours of heat treatment (

), and after exposure to activated carbon at a loading of 0.24% w/w (

), 10% w/w (

) 25% w/w (

), and 50% w/w (

), (according to the concentration of SRE_(6.6)-β-CD), is provided. Thedata shows that exposing the SBE_(6.6)-β-CD solution to heat for 48hours resulted in a significant increase (approximately 95%) in theabsorption maximum at a wavelength of 245 nm to 270 nm. However,treatment with activated carbon decreases the absorption in thiswavelength range. Thus, the drug-degrading impurity having an absorptionat a wavelength of 245 nm to 270 nm increases with heating, but can beremoved through carbon treatment.

Example 34 SBE_(6.6)-β-CD DS and API Stability

Comparative evaluation of various lots of SBE_(6.6)-β-CD processed witha single or a double carbon treatment with an antipsychotic API(aripiprazole) were examined by UV/vis spectrophotometry and HPLCanalysis. The general procedure used to evaluate the stability of theSBE_(6.6)-β-CD/API formulations is provided below.

Aqueous solutions comprising samples of the API (aripiprazole)wereprepared with an API concentration of 7.5 mg/mL and a SBE_(6.6)-β-CDconcentration of 150 mg/mL. Tartaric acid was added to water untildissolved, and the SBE₆₆-β-CD was then added to the tartaric acidsolution. The API was then added to the solutions, and dissolved withinabout 10 minutes of the additions. The mixture was stirred about 1 hour,heated treated, and then filtered through a sterile filter. This processwas performed using the following lots of SBE_(6.6)-β-CD, some of whichunderwent a single treatment with activated carbon and others thatunderwent two treatments with activated carbon (SBE_(6.6)-β-CD Lot Nos.17CX01.HQ00021, 17CX01.HQ00025, 17CX01.HQ00029, 17CX01.HQ00035,17CX01.HQ00036, 17CX01.HQ00037, 17CX01.HQ00038, 17CX01.HQ00039,17CX01.HQ00040, 17CX01.HQ00041, 17CX01.H900042, 17CX01.HQ00043 and17CX01.HQ00044). Solution samples were placed in a stability chamber at50° C. for up to 9 weeks. Samples were removed at 4 weeks and again at 9weeks, and HPLC analysis was performed to determine the extent of APIdegradation.

Aqueous solution samples were analyzed by UV/vis spectrophotometry usingthe following procedure. A 30% w/w β-cyclodextrin solution was preparedby dissolving of the above SBE_(6.6)-β-CD lots (corrected for watercontent) in water. The solution was analyzed in a 1 cm cuvette using aPERKIN ELMER Lambda 35 UV/Vis spectrophotometer, scanning from 190 nm to400 nm at a speed of 240 nm/min and a slit width of 1.0 nm. The sampleswere blanked against water before analysis. The following tables includethe data from this study.

SBE₆₆-β-CD Lot Summary and UV Content

SAE-CD UV Analysis 30% # of (Max Abs SBE_(6.6)-β-CD Carbon @ λ =Solutions Lots Treatments 245-270 nm 17CX01.HQ00021 1 0.2117CX01.HQ00025 1 0.44 17CX01.HQ00029 1 0.21 17CX01.HQ00035 2 0.1617CX01.HQ00036 2 0.14 17CX01.HQ00037 2 0.15 17CX01.HQ00038 2 0.117CX01.HQ00039 2 0.09 17CX01.HQ00040 2 0.09 17CX01.HQ00041 2 0.0817CX01.HQ00042 2 0.07 17CX01.HQ00043 2 0.1 17CX01.HQ00044 2 0.05

SAE-CD & API Impurity Analysis

API Assay SBE_(6.6)-β-CD Δ Assay Δ Assay (150 mg/mL) t = 4 wks (t = 0→   t = 9 wks (t = 0 →   API (7.5 mg/mL) t = 0 @ 50° C. t = 4 wks) @ 50°C. t = 9 wks) 17CX01..HQ00021 0.05 0.90 0.85 1.24 1.19 17CX01.HQ000250.00 1.08 1.08 1.42 1.42 17CX01.HQ00029 0.23 1.04 0.81 1.52 1.2917CX01.HQ00035 0.08 0.63 0.55 0.96 0.88 17CX01.HQ00036 0.08 0.58 0.500.87 0.79 17CX01.HQ00037 0.08 0.65 0.57 0.85 0.77 17CX01.HQ00038 0.070.52 0.45 0.78 0.71 17CX01.HQ00039 0.07 0.55 0.48 0.86 0.7917CX01.HQ00040 0.00 0.21 0.21 0.53 0.53 17CX01.HQ00041 0.00 0.27 0.270.51 0.51 17CX01.HQ00042 0.00 0.34 0.34 0.64 0.64 17CX01.HQ00043 0.070.61 0.54 1.00 0.93 17CX01.HQ00044 0.00 0.13 0.13 0.35 0.35

The data shows that the API undergoes significantly higher degradationwhere it is formulated with an SBE_(6.6)-β-CD lot that has undergoneonly a single treatment with activated carbon. The API formulation thatcontained SBE_(6.6)-β-CD Lot No. 17CX01.HQ00025 had the highestUV-active impurity levels (Max. Abs.=0.44 A.U.) and the API underwent atotal degradation of 1.42% after 9 weeks. SBE_(6.6)-β-CD lots thatunderwent two treatments with activated carbon were measurably lower interms of both levels of UV-active impurities and the extent of APIdegradation. The extent of API degradation that occurred during storagefor 9 weeks at 50° C. correlated with the concentration of UV-activeimpurities present in the formulations. For example, the API formulationcontaining SBE_(6.6)-β-CD Lot No. 17CX01.HQ00044 (which containedUV-active impurities having a Max. Abs.=0.05 A.U.) underwent a totaldegradation of only 0.35% after 9 weeks at 50° C.

FIG. 5 provides a graphical representation of the the correlationbetween the initial UV/vis absorption of the SBE_(6.6)-β-CD lots at awavelength of 245 nm to 270 nm, and the extent of API degradationdetermined at 4 weeks and 9 weeks. Referring to FIG. 5, the data showsthat at both 4 weeks (

) and 9 weeks (

), that the extent of the API degradation increases with theconcentration of the UV/vis absorbing drug-degrading impurities presentin the SBE_(6.6)-β-CD composition.

CONCLUSION

These examples illustrate possible embodiments of the present invention.While various embodiments of the present invention have been describedabove, it should be understood that they have been presented by way ofexample only, and not limitation. It will be apparent to persons skilledin the relevant art that various changes in form and detail can be madetherein without departing from the spirit and scope of the invention.Thus, the breadth and scope of the present invention should not belimited by any of the above-described exemplary embodiments, but shouldbe defined only in accordance with the following claims and theirequivalents.

It is to be appreciated that the Detailed Description section, and notthe Summary and Abstract sections, is intended to be used to interpretthe claims. The Summary and Abstract sections can set tbrth one or more,but not all exemplary embodiments of the present invention ascontemplated by the inventors), and thus, are not intended to limit thepresent invention and the appended claims in any way.

All documents cited herein, including journal articles or abstracts,published or corresponding U.S. or foreign patent applications, issuedor foreign patents, or any other documents, are each entirelyincorporated by reference herein, including all data, tables, figures,and text presented in the cited documents.

1-2. (canceled)
 3. A sulfoalkyl ether cyclodextrin (SAE-CD) compositioncomprising a sulfoalkyl ether cyclodextrin having an average degree ofsubstitution of 4.5 to 7.5, wherein the SAE-CD composition does notcontain phosphate in an amount of 200 ppm or more and does not containunderivatized cyclodextrin in an amount of 0.5% wt. or more, and whereinthe SAE-CD composition has an absorption of less than 0.5 A.U. asdetermined by UV/vis spectrophotometry at a wavelength of 245 nm to 270nm for an aqueous solution containing 300 mg of the SAE-CD compositionper mi. of solution in a cell having a 1 cm path length, wherein theamounts of the phosphate and the underivatized cyclodextrin are withrespect to the SAE-CD composition; and an active agent, wherein theactive agent is an antiviral agent or an antifungal agent.
 4. The SAE-CDcomposition of claim 3, wherein the active agent is an antiviral agent.5. The SAE-CD composition of claim 3, wherein the active agent is anantifungal agent selected from posaconazole or voriconazole.
 6. TheSAE-CD composition of claim 5, wherein the antifungal agent isposaconazole.
 7. The SAE-CD composition of claim 5, wherein theantifungal agent is voriconazole.
 8. The SAE-CD composition of claim 3,wherein the SAE-CD is a cyclodextrin of Formula 1:

wherein p is 4, 5 or 6, and R₁ is independently selected at eachoccurrence from —OH or —O—(C₂-C₆ alkylene)-SO₃ ⁻-T, wherein T isindependently selected at each occurrence from pharmaceuticallyacceptable cations, provided that at least one R₁ is —OH and at leastone R₁ is O—(C₂-C₆ alkylene)-SO₃ ⁻-T.
 9. The SAE-CD composition of claim8, wherein R₁ is independently selected at each occurrence from —OH or—O—(C₄ alkylene)-SO₃ ⁻-T.
 10. The SAE-CD composition of claim 9, wherein-T is Na⁺ at each occurrence.
 11. The SAE-CD composition of claim 8,wherein the pharmaceutically acceptable cation is H⁺, an alkali metalcation, an alkaline earth metal cation, an ammonium ion, and an aminecation.
 12. The SAE-CD composition of claim 8, wherein thepharmaceutically acceptable cation is an alkali metal cation selectedfrom the group consisting of: Li⁺, Na⁺, and
 13. The SAE-CD compositionof claim 8, wherein the pharmaceutically acceptable cation is analkaline earth metal cation selected from the group consisting of: Ca⁺²and Mg⁺².
 14. The SAE-CD composition of claim 8, wherein thepharmaceutically acceptable cation is an amine cation selected from thegroup consisting of: (C1-C6)-alkylamine, pi peridine, pyrazine,(C1-C6)-alkanolamine, ethylenediamine, and (C4-C8)-cycloalkanolamine.15. The SAE-CD composition of claim 3, wherein the average degree ofsubstitution of the sulfoalkyl ether cyclodextrin is 6 to 7.1.
 16. Anoral dosage form comprising the SAE-CD composition of claim
 3. 17. Theoral dosage form of claim 16, wherein the dosage form is a tablet,capsule, or oral suspension.
 18. A reconstitutabie solid dosage formsuitable for injection comprising the SAE-CD composition of claim 3.